{"gene":"MMP3","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1986,"finding":"MMP3 (stromelysin-1) was cloned and its cDNA-derived amino acid sequence determined, revealing it is secreted as a proenzyme with a putative zinc-binding site homologous to thermolysin, and identified as the human ortholog of rat transin.","method":"cDNA cloning and sequence analysis","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — original sequence determination, foundational molecular characterization, highly cited","pmids":["3030290"],"is_preprint":false},{"year":1987,"finding":"Human stromelysin (MMP3) was purified and shown to degrade proteoglycan, fibronectin, laminin, and type IV collagen but not interstitial type I collagen; it is synthesized as a preproenzyme (53,977 Da) and secreted as glycosylated and non-glycosylated proforms; trypsin activation removes 84 amino acids from the N-terminus generating the 45-kDa active enzyme.","method":"Protein purification, substrate cleavage assays, N-terminal sequencing, SDS-PAGE, glycosylation analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — purification with direct substrate assays and biochemical characterization, foundational paper","pmids":["3477804"],"is_preprint":false},{"year":1988,"finding":"The complete primary structure of human MMP-3 (477 residues, 17-residue signal peptide) was determined, confirming identity with stromelysin; MMP-3 and collagenase share 54% sequence identity suggesting common evolutionary origin; IL-1β rapidly induces MMP-3 mRNA in synovial fibroblasts, and retinoic acid or dexamethasone suppresses it.","method":"cDNA sequencing, Northern blot, cytokine/hormone treatment of synovial fibroblast cultures","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — complete primary structure determination with functional gene regulation experiments","pmids":["3360803"],"is_preprint":false},{"year":1990,"finding":"ProMMP-3 activation proceeds through a stepwise mechanism: serine proteinases (neutrophil elastase, plasmin, kallikrein, chymotrypsin) cleave the propeptide at different sites to generate intermediate forms (~53 kDa), which then undergo bimolecular autolytic processing to the fully active 45-kDa species; APMA activates via an intramolecular cleavage at Glu68-Val69 to an intermediate that is then converted by intermolecular reaction; MMP-3 itself cannot activate proMMP-3.","method":"Kinetic analysis, N-terminal sequencing of activation intermediates, in vitro proteinase incubation assays","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — detailed kinetic and sequence analysis of activation mechanism, foundational biochemistry paper","pmids":["2383557"],"is_preprint":false},{"year":1994,"finding":"MMP-3 (along with MMP-1 and MMP-2) produced by human dermal fibroblasts degrades insulin-like growth factor binding protein-3 (IGFBP-3) in vitro, with cleavage sites identified in the mid-region of IGFBP-3, potentially enhancing IGF bioavailability.","method":"IGFBP-3 substrate zymography, immunoaffinity depletion, in vitro cleavage assays with purified MMPs, cleavage site sequencing","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — purified enzyme, defined substrates, cleavage site identification","pmids":["7523391"],"is_preprint":false},{"year":1995,"finding":"Crystal structure of the inhibited catalytic domain and C-truncated proenzyme of stromelysin-1 (MMP-3) was determined by X-ray crystallography; the prodomain forms a separate folding unit with three α-helices and an extended peptide occupying the active site in the reverse direction compared to inhibitors; the catalytic core is similar to collagenases and thermolysin.","method":"X-ray crystallography","journal":"Protein science : a publication of the Protein Society","confidence":"High","confidence_rationale":"Tier 1 — crystal structure determination, foundational structural biology","pmids":["8535233"],"is_preprint":false},{"year":1996,"finding":"A common 5A/6A polymorphism in the MMP3 promoter (1608 bp from transcription start site) differentially binds nuclear proteins and regulates transcription: the 6A allele binds nuclear protein(s) more readily and drives lower reporter gene expression than 5A; this polymorphism is associated with progression of coronary atherosclerosis.","method":"Transient transfection reporter assays (CAT), EMSA, DNase I footprinting","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (transfection + EMSA + footprinting) in one study defining functional promoter variant","pmids":["8662692"],"is_preprint":false},{"year":1997,"finding":"Crystal structure of the MMP-3 catalytic domain in complex with TIMP-1 was solved; TIMP-1 adopts an elongated wedge shape and occupies the entire active-site cleft of MMP-3 along its long edge; Cys1 of TIMP-1 bidentately coordinates the catalytic zinc and Thr2 extends into the S1' specificity pocket, defining the mechanism of MMP-3 inhibition by TIMP-1.","method":"X-ray crystallography of MMP-3/TIMP-1 complex","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure of enzyme-inhibitor complex, foundational","pmids":["9288970"],"is_preprint":false},{"year":1997,"finding":"MMP-3 (along with MMP-2 and MMP-7) degrades decorin (DCN) at identified cleavage sites (including Leu211-Lys in the core protein); MMP-3 and MMP-2 cleave DCN in a similar pattern generating seven major fragments; digestion of a DCN-TGF-β1 complex by MMP-3 releases TGF-β1, suggesting MMPs can liberate ECM-sequestered growth factors.","method":"In vitro cleavage assays with purified MMPs, N-terminal sequencing of fragments, kinetic analysis (Km determination), TGF-β1 release assay","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — purified enzyme, identified substrates and cleavage sites, kinetics, TGF-β1 release measured","pmids":["9148753"],"is_preprint":false},{"year":1999,"finding":"Transgenic expression of MMP3/stromelysin-1 in phenotypically normal mammary epithelial cells induces formation of invasive mesenchymal-like tumors in vivo; MMP3 promotes spontaneous premalignant changes and malignant conversion in mammary glands of transgenic mice; these effects are blocked by co-expression of a TIMP1 transgene, establishing MMP3 as a driver of tumor initiation.","method":"Tetracycline-regulated transgenic mouse model, TIMP1 co-transgenic rescue, histopathology, genomic analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — transgenic gain-of-function with genetic rescue by TIMP1, replicated in multiple mouse models","pmids":["10428026"],"is_preprint":false},{"year":1999,"finding":"MMP3 is a broad-spectrum matrix metalloproteinase with established roles in ECM degradation; key mechanistic features include a prodomain/cysteine-switch mechanism, zinc-dependent catalysis, activation by multiple proteinases, and inhibition by TIMPs.","method":"Review synthesizing biochemical, structural, and cell biology data","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — synthesis of replicated biochemical findings across multiple labs","pmids":["10419448"],"is_preprint":false},{"year":2000,"finding":"MMP-3 (stromelysin-1) cleaves MCP-1, MCP-2, and MCP-4 (monocyte chemoattractant proteins) between residues 4 and 5; the truncated products act as CC chemokine receptor antagonists lacking chemoattractant activity, demonstrating that MMP-3 can modulate inflammatory responses by inactivating chemokines.","method":"In vitro cleavage assays with recombinant MMPs, N-terminal sequencing, receptor binding, calcium flux, chemotaxis assays, in vivo carrageenan inflammation model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 — purified enzyme with substrate identification, cleavage site mapping, in vitro functional assays and in vivo validation","pmids":["12149192"],"is_preprint":false},{"year":2001,"finding":"Osteopontin (OPN) is a novel substrate for MMP-3; three cleavage sites were identified in human OPN (Gly166-Leu167, Ala201-Tyr202, Asp210-Leu211); MMP-3 cleavage of OPN potentiates its function as an adhesive and migratory stimulus through cell-surface integrins, demonstrating that MMP-3 can enhance OPN bioactivity rather than simply degrade it.","method":"In vitro cleavage assays with purified MMP-3, cleavage site sequencing, cell adhesion and migration assays with integrin involvement, in vivo tissue evidence","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — purified enzyme, identified cleavage sites, functional consequences tested with cell assays","pmids":["11375993"],"is_preprint":false},{"year":2002,"finding":"IL-1-induced MMP-3 expression in articular chondrocytes requires activation of ERK, p38, and JNK MAPK pathways, as well as AP-1 and NF-κB transcription factors; pathway-selective inhibitors each partially suppress MMP-3 induction, indicating convergent multi-pathway regulation.","method":"Pharmacological inhibition of MAPK pathways (PD98059, U0126, SB203580, curcumin, PDTC) with RT-PCR and protein readouts in human and bovine chondrocytes","journal":"Matrix biology : journal of the International Society for Matrix Biology","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal inhibitors across two species, replicated findings","pmids":["12009331"],"is_preprint":false},{"year":2003,"finding":"MMP-3 induces secondary and tertiary lateral branching of mammary ducts during mid-puberty and early pregnancy; genetic knockout of MMP-3 impairs this branching, while MMP-2 has distinct roles (inhibiting apoptosis to facilitate terminal end bud invasion and repressing precocious lateral branching), demonstrating site-specific functions of different MMPs in mammary morphogenesis.","method":"Pharmacological inhibition and genetic knockout mouse models (MMP-3 KO, MMP-2 KO, MMP-9 KO), mammary gland whole-mount analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 — genetic loss-of-function with specific morphological phenotype, complemented by pharmacological approach","pmids":["12975354"],"is_preprint":false},{"year":2003,"finding":"Molecular dynamics modeling of MMP-3 in complex with substrate peptides reveals that substrate adopts an antiparallel β-sheet conformation on the P-side; primary substrate selectivity is dominated by sidechains in the S1' pocket and the S2/S3 region (largely hydrophobic); a novel catalytic mechanism is proposed whereby the Zn-ion polarizes the oxygens of the catalytic glutamate to form a nucleophile leading to a tetrahedral oxyanion anhydride transition state.","method":"Molecular dynamics simulations and computational modeling of enzyme-substrate complexes","journal":"Journal of computer-aided molecular design","confidence":"Low","confidence_rationale":"Tier 4 — computational modeling only, no experimental validation in this paper","pmids":["14713188"],"is_preprint":false},{"year":2005,"finding":"MMP-3 cleaves myelin basic protein (MBP), with the citrullinated charge isomer (component-8) being more susceptible to stromelysin-1 cleavage than component-1; cleavage occurs in the presence of lipids and within the context of intact myelin, releasing peptides containing the immunodominant epitope; differences in cleavage rate reflect conformational differences due to post-translational modifications.","method":"In vitro cleavage assays with purified stromelysin-1 and MBP charge isomers, presence of lipids/myelin, peptide fragment identification","journal":"Neurochemical research","confidence":"Medium","confidence_rationale":"Tier 1 — in vitro enzymatic assay with substrate variant comparison, single study","pmids":["16871440"],"is_preprint":false},{"year":2005,"finding":"MMP-3 cleaved MCP-3 at the N-terminus, generating a truncated form that binds CC-chemokine receptors 1, 2, and 3 but does not induce calcium fluxes or chemotaxis, instead acting as a general chemokine antagonist that dampens inflammation in vivo.","method":"In vitro cleavage assays with purified MMP-3, receptor binding assays, calcium flux measurements, in vivo inflammatory model","journal":"Science (New York, N.Y.)","confidence":"High","confidence_rationale":"Tier 1 — purified enzyme with substrate, cleavage site defined, in vitro functional readouts confirmed in vivo","pmids":["10947989"],"is_preprint":false},{"year":2005,"finding":"MMP-3 activity was optimized by developing engineered cleavage sites in a latent cytokine (LAP-mIFNβ) construct; kinetic parameters (kcat/Km) for MMP-1 and MMP-3 cleavage of 15 different linkers were measured by ELISA; introduction of the furin cleavage site-derived hydrophilic sequence increased MMP-3 sensitivity up to 29-fold, establishing substrate design rules for MMP-3 selectivity.","method":"In vitro ELISA-based kinetic assays with purified MMP-1 and MMP-3 against engineered substrates","journal":"Protein engineering, design & selection : PEDS","confidence":"Medium","confidence_rationale":"Tier 1 — kinetic characterization of substrate cleavage, single study, applied context","pmids":["15708865"],"is_preprint":false},{"year":2008,"finding":"MMP-3 inhibition in LPS-stimulated microglia suppresses expression of iNOS and pro-inflammatory cytokines (TNF-α), and reduces activities of NF-κB, AP-1, and MAPK; reactive oxygen species (ROS) act upstream of MMP-3 induction, and MMP-3 inhibition also suppresses ROS production, revealing a bidirectional cross-talk between ROS and MMP-3 in microglial inflammatory signaling.","method":"Pharmacological inhibition of MMP-3 and MMP-9, ROS inhibition (NAC, DPI), NF-κB/AP-1/MAPK activity assays in primary microglia and BV2 cells","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2–3 — pharmacological inhibition with multiple pathway readouts, single study","pmids":["18419763"],"is_preprint":false},{"year":2008,"finding":"AMF/PGI (autocrine motility factor/phosphoglucose isomerase) transactivates the MMP-3 gene promoter through AP-1; this transactivation requires AMF/PGI enzymatic activity and proceeds via stimulation of Src-RhoA-PI3K signaling, with these three molecules forming a complex; the pathway links AMF/PGI-induced MMP-3 expression to hepatoma cell migration.","method":"MMP-3 promoter reporter assays, dominant-negative and pharmacological inhibitors of Src/RhoA/PI3K, co-immunoprecipitation showing Src-RhoA-PI3K complex, migration assays","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 — reporter assay + co-IP + functional migration assay, single lab","pmids":["18571835"],"is_preprint":false},{"year":2011,"finding":"Adiponectin increases MMP-3 secretion in human chondrocytes through AdipoR1 (not AdipoR2) signaling; downstream pathway involves sequential activation of AMPK, p38, and NF-κB, all of which are required for adiponectin-induced MMP-3 promoter activation.","method":"siRNA knockdown of AdipoR1/R2, pharmacological inhibitors of AMPK (araA, compound C), p38 (SB203580), and NF-κB (PDTC, TPCK); qPCR, Western blot, ELISA; NF-κB promoter activity assays in human chondrocytes","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA + pharmacological inhibitors with multiple pathway readouts, single lab","pmids":["21321996"],"is_preprint":false},{"year":2013,"finding":"17β-Estradiol (E2) upregulates MMP3 expression in osteoblasts via ERα signaling; MMP3 then cleaves and solubilizes osteoblast-expressed FasL, generating soluble FasL that induces osteoclast apoptosis; specific MMP3 inhibition or MMP3 siRNA blocks FasL cleavage and preserves osteoclast survival, defining a molecular mechanism for estrogen's bone-protective effects.","method":"EGFP-FasL cleavage fluorescence assay, MMP3-specific inhibitor, MMP3 siRNA, ERαKO mouse osteoblasts, calvarial organ cultures, conditioned media transfer to osteoclast-osteoblast co-cultures","journal":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods (fluorescent reporter, siRNA, KO mice, inhibitor), defined substrate (FasL), functional apoptosis readout","pmids":["22927007"],"is_preprint":false},{"year":2013,"finding":"Phosphorylated STAT3 binds directly to the MMP3 promoter in heme-treated human brain microvascular endothelial cells and transcriptionally activates MMP3 expression; heme-induced MMP3 upregulation via STAT3 promotes endothelial cell apoptosis.","method":"ChIP assay, luciferase reporter assay with human MMP3 promoter, qRT-PCR, Western blot, MTT and TUNEL apoptosis assays, RT² Profile PCR arrays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP + reporter assay + functional apoptosis readout, single lab","pmids":["23967200"],"is_preprint":false},{"year":2013,"finding":"MMP-3 mediates psychosine-induced globoid cell (multinucleated microglia) formation; exposure to psychosine induces MMP-3 expression in primary glial cultures, and genetic ablation or chemical inhibition of MMP-3 prevents the morphological transformation of microglia into globoid cells; this effect is microglia-specific, not seen in peripheral macrophages.","method":"Primary glial cultures, MMP-3 knockout mice, pharmacological MMP-3 inhibition, psychosine treatment, twitcher mouse model, bone marrow transplantation","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 — genetic KO + chemical inhibition with specific cellular phenotype in primary cultures and disease model","pmids":["23404611"],"is_preprint":false},{"year":2013,"finding":"NFATc3 is a transcriptional activator of Mmp3 in astrocytes; constitutively active NFATc3 overexpression induces Mmp3 mRNA and protein selectively (not other MMPs or TIMPs); calcium ionophore and ATP-induced Mmp3 upregulation is blocked by the calcineurin inhibitor cyclosporin A and by actinomycin D; a Mmp3 promoter reporter is activated by increased intracellular calcium; in vivo, MMP3 is expressed in NFATc3-positive scar-forming astrocytes after brain injury.","method":"Constitutively active NFATc3 overexpression, calcium ionophore/BzATP treatment, CsA inhibition, Mmp3 promoter luciferase reporter, pure astrocyte cultures from neural stem cells, in vivo stab-wound model","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (OE, pharmacological inhibition, reporter assay, in vivo), replicated in pure astrocyte system","pmids":["23625833"],"is_preprint":false},{"year":2014,"finding":"MMP3 stimulates expression of Rac1b (a tumorigenic splice isoform of Rac1) in pancreatic cancer cells; recombinant MMP3 treatment increases cellular invasiveness and activates tumorigenic transcriptional profiles; in transgenic mice, co-expression of MMP3 with activated KRAS in pancreatic acinar cells stimulates metaplasia and immune cell infiltration, priming the tumor microenvironment.","method":"Human PDA tissue biopsy analysis, transgenic mouse models (MMP3 + KRAS co-expression), recombinant MMP3 treatment of cultured pancreatic cancer cells, invasion assays","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 2 — transgenic in vivo model + recombinant protein treatment + patient tissue validation","pmids":["24850902"],"is_preprint":false},{"year":2015,"finding":"IRF8 directly represses MMP3 transcription; IRF8-loss leads to elevated MMP3 expression; silencing MMP3 in IRF8-null tumor cells significantly reduces their growth advantage and decreases spontaneous lung metastasis in an orthotopic mammary carcinoma model, defining an IRF8-MMP3 transcriptional axis in tumor progression.","method":"Gene expression profiling, MMP3 silencing in IRF8-null cells, orthotopic mouse mammary tumor model, lung metastasis quantification","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined in vivo phenotype, single lab","pmids":["26008967"],"is_preprint":false},{"year":2016,"finding":"NFAT1 (NFATC2) directly regulates MMP3 transcription in melanoma; NFAT1 depletion reduces MMP3 expression, while NFAT1 overexpression induces it; restoration of NFAT1 recovers MMP3 levels; in vivo, MMP3 promotes melanoma tumor growth and lung metastasis downstream of NFAT1.","method":"Stable NFAT1 silencing, microarray, restoration experiments, in vivo tumor growth and metastasis assays","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with in vivo validation, single lab","pmids":["27013197"],"is_preprint":false},{"year":2016,"finding":"MMP3 acts as an antiadipogenic factor in adipose progenitor cells (APCs); MMP3 enzymatic activity inhibits differentiation of 3T3-L1 preadipocytes and primary human preadipocytes; TIMP4 attenuates the inhibitory effect of MMP3 on adipogenesis; HFD-induced obesity downregulates APC MMP3 to trigger adipogenesis in a sex- and depot-dependent manner.","method":"Overexpression of Mmp3 in 3T3-L1 preadipocytes, recombinant human MMP3 and TIMP4 treatment of primary human preadipocytes, differentiation assays, HFD mouse model","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 1–2 — recombinant protein treatment with functional differentiation readout, in vivo validation in mouse model","pmids":["27879248"],"is_preprint":false},{"year":2017,"finding":"BMAL1 deficiency upregulates MMP3 expression through activation of p65 (NF-κB) phosphorylation; in BMAL1-deficient mice, Mmp3 is upregulated throughout growth period; MMP3 upregulation contributes to mandibular dysplasia (skeletal mandibular hypoplasia), linking the circadian clock component BMAL1 to MMP3-mediated craniofacial development.","method":"RNA sequencing, protein chip analysis, Bmal1 KO mice, NF-κB phosphorylation analysis, human patient samples","journal":"Stem cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — KO model with defined molecular mechanism (p65 phosphorylation), human correlation","pmids":["29276151"],"is_preprint":false},{"year":2019,"finding":"IL-1β-induced MMP-3 expression in dermal fibroblasts requires ERK1 (not ERK2) to phosphorylate ATF-2, which then transcriptionally activates MMP-3; ERK inhibition abolishes ATF-2 phosphorylation and MMP-3 induction; ERK1 siRNA but not ERK2 siRNA reduces ATF-2 phosphorylation, revealing an ERK1/ATF-2 axis specific to MMP-3 expression.","method":"siRNA knockdown of ERK1 and ERK2 separately, ATF-2 siRNA, ATF-2 inhibitor (SBI-0087702), ERK inhibitor (FR180204), Western blot of phosphorylation, RT-PCR of MMP-3 mRNA in dermal fibroblasts","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific siRNA distinguishing ERK1 vs ERK2, multiple inhibitors, single lab","pmids":["31536594"],"is_preprint":false},{"year":2020,"finding":"MMP3 knockout in tumor cells (CRISPR/Cas9) reduces tumoroid size, promotes necrotic areas within tumoroids, and results in additional release of broken extracellular vesicles; MMP3-rich EVs from wild-type tumoroids deeply penetrate MMP3-KO tumoroids and rescue proliferation and tumorigenesis, demonstrating that MMP3 can be transferred via EVs to regulate tumor growth.","method":"CRISPR/Cas9 MMP3 KO, 3D tumoroid culture, EV isolation and characterization (NanoSight), fluorescent EV tracking, conditioned medium rescue experiments, Ki-67 staining","journal":"Cancers","confidence":"Medium","confidence_rationale":"Tier 2 — CRISPR KO with EV rescue experiment, novel mechanism, single lab","pmids":["32429403"],"is_preprint":false},{"year":2020,"finding":"MMP-3 ablation in prostate cancer cells reduces AKT and ERK phosphorylation and total VEGFR1 and FGFR3 protein levels, decreasing intrinsic cell growth; tumor-derived MMP-3 also promotes angiogenesis extrinsically, as MMP-3-ablated conditioned media slows endothelial tube formation; in vivo MMP-3-ablated tumors grow slower and are less vascularized.","method":"MMP-3 siRNA ablation in prostate cancer cell lines, in vitro growth assays, Western blot for AKT/ERK/VEGFR1/FGFR3, endothelial tube formation assays with conditioned media, in vivo tumor growth and vascularization","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with in vitro and in vivo validation, multiple pathway readouts, single lab","pmids":["32896761"],"is_preprint":false},{"year":2021,"finding":"MMP3 deficiency (KO mice or MMP3 inhibition) increases blood-brain barrier integrity by preserving tight junction (TJ) and VE-cadherin proteins; conversely, MMP3 upregulation reduces TJ and VE-cadherin abundance in brain microvascular endothelial cells; the effect requires ERK signaling, as an ERK inhibitor blocks MMP3-mediated reduction of TJ proteins; MMP3-KO mice show reduced dye extravasation and altered anesthesia kinetics consistent with improved BBB function.","method":"MMP3 KO mice, TEER and Transwell barrier assays, dye extravasation in vivo, TJ/VE-cadherin Western blot, ERK inhibitor treatment","journal":"Oxidative medicine and cellular longevity","confidence":"Medium","confidence_rationale":"Tier 2 — KO + inhibitor + in vivo and in vitro barrier assays, ERK pathway mechanistically linked, single lab","pmids":["33859779"],"is_preprint":false},{"year":2021,"finding":"GBP5 promotes glioblastoma aggressiveness through activation of the Src/ERK1/2/MMP3 axis; GBP5 overexpression increases MMP3, and silencing GBP5 reduces MMP3-dependent proliferation, migration, and invasion in vitro and impairs tumor growth in vivo.","method":"GBP5 overexpression and siRNA knockdown in GBM cell lines, in vitro migration/invasion/proliferation assays, in vivo tumor implantation, Src/ERK1/2 pathway inhibitors","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with in vivo validation, pathway inhibitors used, single lab","pmids":["33608513"],"is_preprint":false},{"year":2023,"finding":"IGF2BP3 binds and stabilizes MMP3 mRNA through interaction with N6-methyladenosine (m6A) modification; IGF2BP3 promotes cardiomyocyte proliferation and cardiac regeneration after myocardial infarction; MMP3 acts downstream of IGF2BP3 to regulate cardiomyocyte proliferation, as functional analyses of MMP3 itself show it mediates this regenerative effect.","method":"Gain- and loss-of-function of IGF2BP3 in vitro and in vivo (mouse MI model), RIP assay showing IGF2BP3-MMP3 mRNA interaction, m6A modification analysis, MMP3 functional assays in cardiomyocytes","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 — RIP demonstrates mRNA-protein interaction, gain/loss-of-function in vivo, novel post-transcriptional mechanism, single lab","pmids":["37188676"],"is_preprint":false},{"year":2024,"finding":"Loss of histone methyltransferases KMT2C or KMT2D drives brain metastasis in triple-negative breast cancer via KDM6A-dependent upregulation of MMP3; global chromatin profiling showed altered H3K4me1, H3K27ac, and H3K27me3 marks in KO cells; KDM6A binding at the Mmp3 locus correlates with its increased expression; pharmacological inhibition of KDM6A or direct Mmp3 knockdown prevents brain metastasis equivalently.","method":"Kmt2c/Kmt2d KO mouse models, ChIP-seq (H3K4me1, H3K27ac, H3K27me3, KDM6A), RNA-seq, KDM6A inhibition, Mmp3 shRNA, in vivo brain metastasis assays, human KMT2C-mutant TNBC patient samples","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 1–2 — multi-omic chromatin profiling + genetic KO + pharmacological inhibition + in vivo validation + human patient correlation","pmids":["38926506"],"is_preprint":false}],"current_model":"MMP3 (stromelysin-1) is a secreted zinc-dependent endopeptidase that is synthesized as a proenzyme activated stepwise by serine proteinases and autocatalytic intermolecular cleavage; its crystal structure reveals a catalytic zinc coordinated by TIMP-1's Cys1 for inhibition and a S1' specificity pocket governing substrate selectivity; MMP3 degrades a broad range of ECM substrates (proteoglycan, fibronectin, laminin, type IV collagen, decorin, IGFBP-3, osteopontin, myelin basic protein) and cleaves chemokines (MCP-1/2/3/4) to generate receptor antagonists that dampen inflammation; transcriptionally, MMP3 is induced by IL-1β, TNF-α, and adiponectin through convergent MAPK (ERK, p38, JNK), NF-κB, and AP-1 pathways, with the ERK1/ATF-2 axis specifically required in fibroblasts, NFAT1/NFATc3 mediating Ca²⁺-dependent induction in T cells and astrocytes, and STAT3 directly binding its promoter in endothelial cells; the 5A/6A promoter polymorphism alters transcription factor binding and MMP3 expression levels; MMP3 drives epithelial-to-mesenchymal transition and tumor initiation, activates Rac1b signaling in pancreatic cancer, cleaves FasL to solubilize it and promote osteoclast apoptosis downstream of estrogen/ERα signaling, increases blood-brain barrier permeability via ERK-dependent TJ protein degradation, and its mRNA stability is post-transcriptionally regulated by IGF2BP3 through m6A recognition; epigenetically, KMT2C/D loss upregulates MMP3 through KDM6A-mediated H3K27me3 demethylation, driving brain metastasis."},"narrative":{"teleology":[{"year":1986,"claim":"Cloning of MMP3 cDNA established it as a secreted proenzyme with a zinc-binding catalytic domain homologous to thermolysin, placing it within the matrix metalloproteinase family.","evidence":"cDNA cloning and sequence analysis from human fibroblasts","pmids":["3030290"],"confidence":"High","gaps":["No enzymatic activity demonstrated","No substrates identified","Activation mechanism unknown"]},{"year":1987,"claim":"Biochemical characterization of purified MMP3 defined its ECM substrate repertoire (proteoglycan, fibronectin, laminin, type IV collagen) and showed trypsin-mediated N-terminal propeptide removal generates the active 45-kDa enzyme.","evidence":"Protein purification, substrate cleavage assays, N-terminal sequencing, SDS-PAGE","pmids":["3477804"],"confidence":"High","gaps":["Physiological activating proteinases unidentified","Structural basis of catalysis unknown"]},{"year":1990,"claim":"Detailed kinetic dissection revealed that proMMP-3 activation is a stepwise process: serine proteinases cleave the propeptide at distinct sites to generate intermediates, followed by bimolecular autolytic processing to the fully active species—establishing the activation cascade as a regulated multi-step event.","evidence":"Kinetic analysis and N-terminal sequencing of activation intermediates in vitro","pmids":["2383557"],"confidence":"High","gaps":["In vivo relevance of individual serine proteinase activators not tested","Cysteine-switch mechanism structurally unresolved"]},{"year":1995,"claim":"Crystal structures of the proenzyme and catalytic domain of MMP3 resolved the cysteine-switch mechanism: the prodomain occupies the active site in reverse orientation relative to substrates, explaining latency.","evidence":"X-ray crystallography of proenzyme and catalytic domain","pmids":["8535233"],"confidence":"High","gaps":["Inhibitor-bound structure not yet available","S1' pocket substrate selectivity rules not defined structurally"]},{"year":1996,"claim":"Identification of a functional 5A/6A promoter polymorphism showed that differential nuclear protein binding regulates MMP3 transcriptional output, linking genetic variation to disease-relevant expression differences.","evidence":"CAT reporter assay, EMSA, DNase I footprinting in human cells","pmids":["8662692"],"confidence":"High","gaps":["Identity of the repressor protein(s) binding the 6A allele unknown","Mechanism of allele-specific regulation incomplete"]},{"year":1997,"claim":"The MMP3–TIMP-1 co-crystal structure defined the inhibition mechanism: TIMP-1 Cys1 bidentately coordinates the catalytic zinc, and Thr2 inserts into the S1' pocket, explaining both broad MMP inhibition and specificity determinants.","evidence":"X-ray crystallography of MMP-3/TIMP-1 complex","pmids":["9288970"],"confidence":"High","gaps":["TIMP-2/3/4 inhibition mechanisms not compared structurally","Dynamics of TIMP displacement during activation not studied"]},{"year":1997,"claim":"Discovery that MMP3 cleaves decorin to release sequestered TGF-β1 expanded MMP3 function from simple ECM degradation to growth factor mobilization.","evidence":"In vitro cleavage assays with purified enzyme, N-terminal sequencing, TGF-β1 release assay","pmids":["9148753"],"confidence":"High","gaps":["In vivo physiological relevance of decorin-TGF-β1 release by MMP3 not demonstrated"]},{"year":1999,"claim":"Transgenic MMP3 expression in mammary epithelium was sufficient to drive epithelial-to-mesenchymal transition and invasive tumor formation, rescued by TIMP1 co-expression, establishing MMP3 as a tumor initiator rather than merely a progression factor.","evidence":"Tet-regulated transgenic mouse, TIMP1 rescue, histopathology","pmids":["10428026"],"confidence":"High","gaps":["Substrate(s) mediating EMT not identified","Relevance to human breast cancer initiation not directly shown"]},{"year":2000,"claim":"MMP3 cleavage of MCP chemokines between residues 4 and 5 generates truncated forms that act as receptor antagonists, revealing a novel anti-inflammatory role for MMP3 in modulating chemokine signaling.","evidence":"Purified enzyme cleavage, N-terminal sequencing, receptor binding, chemotaxis, and in vivo inflammation model","pmids":["10947989","12149192"],"confidence":"High","gaps":["Relative in vivo contribution of MMP3 versus other MCPs-processing MMPs not resolved"]},{"year":2002,"claim":"Mapping of IL-1β-induced MMP3 transcription demonstrated convergent requirement for ERK, p38, JNK MAPK cascades plus AP-1 and NF-κB, establishing MMP3 as a hub target of multiple inflammatory signaling arms.","evidence":"Pharmacological MAPK inhibitors with RT-PCR readouts in human and bovine chondrocytes","pmids":["12009331"],"confidence":"High","gaps":["Relative contribution of each pathway under physiological stimulus concentrations unclear","Promoter elements for each TF not mapped"]},{"year":2013,"claim":"Multiple studies revealed cell-type-specific transcriptional regulators of MMP3: NFATc3 drives calcium-dependent MMP3 induction in astrocytes, STAT3 activates MMP3 in brain endothelial cells, and estrogen/ERα induces MMP3 in osteoblasts where it cleaves FasL to control osteoclast apoptosis.","evidence":"Constitutively active NFATc3 OE/CsA inhibition/reporter in astrocytes; ChIP/reporter for STAT3 in endothelial cells; EGFP-FasL cleavage assay/MMP3 siRNA/ERαKO osteoblasts","pmids":["23625833","23967200","22927007"],"confidence":"High","gaps":["Whether NFATc3 vs STAT3 vs ERα pathways converge on shared promoter elements is unknown","FasL cleavage site not determined"]},{"year":2014,"claim":"MMP3 was shown to stimulate Rac1b expression in pancreatic cancer cells and cooperate with oncogenic KRAS to drive acinar-to-ductal metaplasia and immune infiltration, defining a non-ECM signaling role in pancreatic tumorigenesis.","evidence":"Transgenic mice (MMP3 + KRAS), recombinant MMP3 treatment of cancer cells, invasion assays, human tissue analysis","pmids":["24850902"],"confidence":"High","gaps":["Mechanism by which MMP3 induces Rac1b splicing not identified","Direct versus indirect Rac1b regulation unclear"]},{"year":2019,"claim":"ERK1 (not ERK2) was identified as the specific isoform phosphorylating ATF-2 to drive IL-1β-induced MMP3 expression in dermal fibroblasts, refining the MAPK-to-MMP3 signaling axis.","evidence":"Isoform-specific ERK1/ERK2 siRNA, ATF-2 inhibitor, Western blot of phospho-ATF-2","pmids":["31536594"],"confidence":"Medium","gaps":["Whether ERK1 specificity applies beyond dermal fibroblasts is untested","Single lab, not independently replicated"]},{"year":2021,"claim":"MMP3 disrupts blood–brain barrier integrity through ERK-dependent degradation of tight junction and VE-cadherin proteins, demonstrated by MMP3 KO mice showing preserved barrier function and reduced dye extravasation.","evidence":"MMP3 KO mice, TEER/Transwell assays, in vivo dye extravasation, ERK inhibitor rescue","pmids":["33859779"],"confidence":"Medium","gaps":["Direct TJ protein cleavage sites not mapped","Contribution of MMP3 versus secondary signaling to TJ loss not dissected"]},{"year":2023,"claim":"Post-transcriptional regulation of MMP3 mRNA by IGF2BP3 through m6A recognition was identified, demonstrating that MMP3 output is controlled at the mRNA stability level in addition to transcriptional regulation, with functional relevance to cardiomyocyte proliferation and cardiac regeneration.","evidence":"RIP assay for IGF2BP3–MMP3 mRNA interaction, m6A analysis, gain/loss-of-function in mouse MI model","pmids":["37188676"],"confidence":"Medium","gaps":["Specific m6A sites on MMP3 mRNA not mapped","Whether this mechanism operates in non-cardiac contexts unknown"]},{"year":2024,"claim":"Epigenetic derepression of MMP3 via KDM6A-mediated H3K27me3 removal upon KMT2C/D loss was shown to be necessary and sufficient for brain metastasis in triple-negative breast cancer, establishing MMP3 as a critical effector downstream of chromatin dysregulation.","evidence":"KMT2C/D KO mice, ChIP-seq (H3K4me1/H3K27ac/H3K27me3/KDM6A), MMP3 shRNA, KDM6A inhibitor, in vivo brain metastasis, human TNBC samples","pmids":["38926506"],"confidence":"High","gaps":["Whether MMP3 is the sole mediator of KMT2C/D-loss brain metastasis or one of several effectors is unresolved","Substrate(s) mediating BBB crossing not identified"]},{"year":null,"claim":"Key unresolved questions include the identity of direct MMP3 substrate(s) mediating EMT and brain metastasis, the structural basis for Rac1b induction, whether extracellular vesicle–mediated MMP3 transfer is physiologically significant, and comprehensive mapping of MMP3 cleavage sites in the degradome in vivo.","evidence":"","pmids":[],"confidence":"Low","gaps":["No in vivo degradomic/TAILS study of MMP3 substrates","EV-mediated MMP3 delivery lacks independent validation","Rac1b induction mechanism completely uncharacterized"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,3,4,8,11,12,16,17,22]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,3,4,8,11,12]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[1,9,32]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[1,8,12]}],"pathway":[{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[1,8,12,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,26,27,28,37]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11,17]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,21,31,34]}],"complexes":[],"partners":["TIMP1","NFATC3","IGF2BP3","KDM6A","STAT3","IRF8"],"other_free_text":[]},"mechanistic_narrative":"MMP3 (stromelysin-1) is a secreted zinc-dependent endopeptidase synthesized as a proenzyme and activated stepwise by serine proteinases and autocatalytic intermolecular cleavage, with its catalytic zinc coordinated by conserved histidines and inhibited by TIMP-1 through bidentate Cys1–zinc chelation [PMID:3477804, PMID:2383557, PMID:9288970]. MMP3 degrades a broad spectrum of ECM substrates—including proteoglycan, fibronectin, laminin, type IV collagen, decorin, IGFBP-3, osteopontin, and myelin basic protein—and processes chemokines (MCP-1/2/3/4) into receptor antagonists that dampen inflammation, as well as cleaving FasL to promote osteoclast apoptosis downstream of estrogen/ERα signaling [PMID:3477804, PMID:9148753, PMID:12149192, PMID:22927007]. Transcription of MMP3 is induced by IL-1β, TNF-α, and adiponectin through convergent ERK/p38/JNK MAPK, NF-κB, and AP-1 pathways, with additional regulation by NFAT, STAT3, IRF8, and BMAL1, and a functional 5A/6A promoter polymorphism that modulates expression levels; post-transcriptionally, IGF2BP3 stabilizes MMP3 mRNA via m6A recognition [PMID:12009331, PMID:8662692, PMID:23625833, PMID:37188676]. MMP3 drives epithelial-to-mesenchymal transition, mammary tumor initiation, Rac1b-dependent pancreatic cancer progression, blood–brain barrier permeability via ERK-dependent tight junction degradation, and brain metastasis upon epigenetic derepression by KDM6A following KMT2C/D loss [PMID:10428026, PMID:24850902, PMID:33859779, PMID:38926506]."},"prefetch_data":{"uniprot":{"accession":"P08254","full_name":"Stromelysin-1","aliases":["Matrix metalloproteinase-3","MMP-3","Transin-1"],"length_aa":477,"mass_kda":54.0,"function":"Metalloproteinase with a rather broad substrate specificity that can degrade fibronectin, laminin, gelatins of type I, III, IV, and V; collagens III, IV, X, and IX, and cartilage proteoglycans. Activates different molecules including growth factors, plasminogen or other matrix metalloproteinases such as MMP9 (PubMed:11029580, PubMed:1371271). Once released into the extracellular matrix (ECM), the inactive pro-enzyme is activated by the plasmin cascade signaling pathway (PubMed:2383557). Also acts intracellularly (PubMed:22265821). For example, in dopaminergic neurons, gets activated by the serine protease HTRA2 upon stress and plays a pivotal role in DA neuronal degeneration by mediating microglial activation and alpha-synuclein/SNCA cleavage (PubMed:21330369). In addition, plays a role in immune response and possesses antiviral activity against various viruses such as vesicular stomatitis virus, influenza A virus (H1N1) and human herpes virus 1 (PubMed:35940311). Mechanistically, translocates from the cytoplasm into the cell nucleus upon virus infection to influence NF-kappa-B activities (PubMed:35940311)","subcellular_location":"Secreted, extracellular space, extracellular matrix; Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P08254/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MMP3","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MMP3","total_profiled":1310},"omim":[{"mim_id":"614466","title":"CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 6; CHDS6","url":"https://www.omim.org/entry/614466"},{"mim_id":"609951","title":"ZINC FINGER PROTEIN 384; ZNF384","url":"https://www.omim.org/entry/609951"},{"mim_id":"608482","title":"MATRIX METALLOPROTEINASE 25; MMP25","url":"https://www.omim.org/entry/608482"},{"mim_id":"607339","title":"CORONARY HEART DISEASE, SUSCEPTIBILITY TO, 1","url":"https://www.omim.org/entry/607339"},{"mim_id":"605470","title":"MATRIX METALLOPROTEINASE 26; MMP26","url":"https://www.omim.org/entry/605470"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adipose tissue","ntpm":99.1},{"tissue":"salivary gland","ntpm":285.6},{"tissue":"skin 1","ntpm":72.2}],"url":"https://www.proteinatlas.org/search/MMP3"},"hgnc":{"alias_symbol":[],"prev_symbol":["STMY1","STMY"]},"alphafold":{"accession":"P08254","domains":[{"cath_id":"3.40.390.10","chopping":"114-264","consensus_level":"high","plddt":93.6172,"start":114,"end":264},{"cath_id":"2.110.10.10","chopping":"299-476","consensus_level":"high","plddt":91.9488,"start":299,"end":476}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08254","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08254-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08254-F1-predicted_aligned_error_v6.png","plddt_mean":85.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MMP3","jax_strain_url":"https://www.jax.org/strain/search?query=MMP3"},"sequence":{"accession":"P08254","fasta_url":"https://rest.uniprot.org/uniprotkb/P08254.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08254/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08254"}},"corpus_meta":[{"pmid":"10428026","id":"PMC_10428026","title":"The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.","date":"1999","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10428026","citation_count":726,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12975354","id":"PMC_12975354","title":"Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis.","date":"2003","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12975354","citation_count":239,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16158251","id":"PMC_16158251","title":"Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model.","date":"2005","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/16158251","citation_count":174,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15135145","id":"PMC_15135145","title":"Increased stromelysin-1 (MMP-3), proteoglycan degradation (3B3- and 7D4) and collagen damage in cyclically load-injured articular cartilage.","date":"2004","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/15135145","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18419763","id":"PMC_18419763","title":"Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18419763","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19042922","id":"PMC_19042922","title":"Variants within the MMP3 gene are associated with Achilles tendinopathy: possible interaction with the COL5A1 gene.","date":"2008","source":"British journal of sports medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19042922","citation_count":119,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10558909","id":"PMC_10558909","title":"Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10558909","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31174824","id":"PMC_31174824","title":"MMP3 is a reliable marker for disease activity, radiological monitoring, disease outcome predictability, and therapeutic response in rheumatoid arthritis.","date":"2019","source":"Best practice & research. Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/31174824","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16100390","id":"PMC_16100390","title":"Osteoactivin upregulates expression of MMP-3 and MMP-9 in fibroblasts infiltrated into denervated skeletal muscle in mice.","date":"2005","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16100390","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10670469","id":"PMC_10670469","title":"Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts.","date":"2000","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/10670469","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8611434","id":"PMC_8611434","title":"Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease.","date":"1996","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8611434","citation_count":81,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27013197","id":"PMC_27013197","title":"NFAT1 Directly Regulates IL8 and MMP3 to Promote Melanoma Tumor Growth and Metastasis.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27013197","citation_count":80,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21321996","id":"PMC_21321996","title":"Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 signaling pathway.","date":"2011","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21321996","citation_count":79,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19056796","id":"PMC_19056796","title":"Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts.","date":"2009","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19056796","citation_count":74,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27879248","id":"PMC_27879248","title":"High-fat diet-induced obesity regulates MMP3 to modulate depot- and sex-dependent adipose expansion in C57BL/6J mice.","date":"2016","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27879248","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11438501","id":"PMC_11438501","title":"A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis.","date":"2001","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/11438501","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15341739","id":"PMC_15341739","title":"Positive selection on MMP3 regulation has shaped heart disease risk.","date":"2004","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/15341739","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24507680","id":"PMC_24507680","title":"Expression and significance of MMP3 in synovium of knee joint at different stage in osteoarthritis patients.","date":"2014","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24507680","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22927007","id":"PMC_22927007","title":"ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis.","date":"2013","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/22927007","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26873249","id":"PMC_26873249","title":"Explore the variation of MMP3, JNK, p38 MAPKs, and autophagy at the early stage of osteoarthritis.","date":"2016","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/26873249","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24850902","id":"PMC_24850902","title":"Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma.","date":"2014","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/24850902","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18007247","id":"PMC_18007247","title":"Association between IL-6 and MMP-3 gene polymorphisms and adolescent idiopathic scoliosis: a case-control study.","date":"2007","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/18007247","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29483840","id":"PMC_29483840","title":"MiR-519d suppresses breast cancer tumorigenesis and metastasis via targeting MMP3.","date":"2018","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29483840","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28447732","id":"PMC_28447732","title":"Icariin inhibits MMP‑1, MMP‑3 and MMP‑13 expression through MAPK pathways in IL‑1β‑stimulated SW1353 chondrosarcoma cells.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28447732","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32429403","id":"PMC_32429403","title":"Knockout of MMP3 Weakens Solid Tumor Organoids and Cancer Extracellular Vesicles.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32429403","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33859779","id":"PMC_33859779","title":"Increase in Blood-Brain Barrier (BBB) Permeability Is Regulated by MMP3 via the ERK Signaling Pathway.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/33859779","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22615070","id":"PMC_22615070","title":"Impaired biomechanical properties correlate with neoangiogenesis as well as VEGF and MMP-3 expression during rat patellar tendon healing.","date":"2012","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/22615070","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16862557","id":"PMC_16862557","title":"Upregulation of matrix metalloproteinase (MMP)-1 and its activator MMP-3 of human osteoblast by uniaxial cyclic stimulation.","date":"2007","source":"Journal of biomedical materials research. Part B, Applied biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/16862557","citation_count":48,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21667159","id":"PMC_21667159","title":"Cyclophilin A promotes human hepatocellular carcinoma cell metastasis via regulation of MMP3 and MMP9.","date":"2011","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21667159","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23769926","id":"PMC_23769926","title":"Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23769926","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16871440","id":"PMC_16871440","title":"Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope.","date":"2006","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/16871440","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22671570","id":"PMC_22671570","title":"MMP3 and TIMP1 variants contribute to chronic periodontitis and may be implicated in disease progression.","date":"2012","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/22671570","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28961241","id":"PMC_28961241","title":"Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28961241","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33608513","id":"PMC_33608513","title":"GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33608513","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18832569","id":"PMC_18832569","title":"Keratinocyte expression of MMP3 enhances differentiation and prevents tumor establishment.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18832569","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32896761","id":"PMC_32896761","title":"Prostate cancer-derived MMP-3 controls intrinsic cell growth and extrinsic angiogenesis.","date":"2020","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32896761","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25956994","id":"PMC_25956994","title":"TNF-α stimulates MMP-3 production via PGE2 signalling through the NF-kB and p38 MAPK pathway in a murine cementoblast cell line.","date":"2015","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/25956994","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22222271","id":"PMC_22222271","title":"Involvement of SPARC and MMP-3 in the pathogenesis of human pterygium.","date":"2012","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/22222271","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14713188","id":"PMC_14713188","title":"Modeling of enzyme-substrate complexes for the metalloproteases MMP-3, ADAM-9 and ADAM-10.","date":"2003","source":"Journal of computer-aided molecular design","url":"https://pubmed.ncbi.nlm.nih.gov/14713188","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29276151","id":"PMC_29276151","title":"BMAL1 Deficiency Contributes to Mandibular Dysplasia by Upregulating MMP3.","date":"2017","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29276151","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23404611","id":"PMC_23404611","title":"MMP-3 mediates psychosine-induced globoid cell formation: implications for leukodystrophy pathology.","date":"2013","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/23404611","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22836729","id":"PMC_22836729","title":"Substance P enhances collagen remodeling and MMP-3 expression by human tenocytes.","date":"2012","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/22836729","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38926506","id":"PMC_38926506","title":"Loss of Kmt2c or Kmt2d drives brain metastasis via KDM6A-dependent upregulation of MMP3.","date":"2024","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38926506","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22114952","id":"PMC_22114952","title":"Regulation of MMP-3 expression and secretion by the chemokine eotaxin-1 in human chondrocytes.","date":"2011","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/22114952","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31452735","id":"PMC_31452735","title":"HTR1D, TIMP1, SERPINE1, MMP3 and CNR2 affect the survival of patients with colon adenocarcinoma.","date":"2019","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31452735","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24999605","id":"PMC_24999605","title":"MMP3 and CXCL1 are potent stromal protein markers of dysplasia-carcinoma transition in sporadic colorectal cancer.","date":"2014","source":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)","url":"https://pubmed.ncbi.nlm.nih.gov/24999605","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27222816","id":"PMC_27222816","title":"MMP3 and TIMP2 gene variants as predisposing factors for Achilles tendon pathologies: Attempted replication study in a British case-control cohort.","date":"2016","source":"Meta gene","url":"https://pubmed.ncbi.nlm.nih.gov/27222816","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28265573","id":"PMC_28265573","title":"Autophagy Protects Advanced Glycation End Product-Induced Apoptosis and Expression of MMP-3 and MMP-13 in Rat Chondrocytes.","date":"2017","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/28265573","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32131874","id":"PMC_32131874","title":"The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3.","date":"2020","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/32131874","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25746423","id":"PMC_25746423","title":"Berberine inhibits Chlamydia pneumoniae infection-induced vascular smooth muscle cell migration through downregulating MMP3 and MMP9 via PI3K.","date":"2015","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25746423","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31258780","id":"PMC_31258780","title":"Dysregulation of MiR-519d Affects Oral Squamous Cell Carcinoma Invasion and Metastasis by Targeting MMP3.","date":"2019","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31258780","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23967200","id":"PMC_23967200","title":"STAT3 regulates MMP3 in heme-induced endothelial cell apoptosis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23967200","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15642131","id":"PMC_15642131","title":"MMP-3 expression and release by rheumatoid arthritis fibroblast-like synoviocytes induced with a bacterial ligand of integrin alpha5beta1.","date":"2004","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15642131","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19463894","id":"PMC_19463894","title":"Increased MMP-3 and CTGF expression during lipopolysaccharide-induced dopaminergic neurodegeneration.","date":"2009","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/19463894","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23108733","id":"PMC_23108733","title":"The polymorphisms of the MMP-1 and the MMP-3 genes and the risk of pelvic organ prolapse.","date":"2012","source":"International urogynecology journal","url":"https://pubmed.ncbi.nlm.nih.gov/23108733","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27211292","id":"PMC_27211292","title":"The MMP3 gene in musculoskeletal soft tissue injury risk profiling: A study in two independent sample groups.","date":"2016","source":"Journal of sports sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27211292","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24648922","id":"PMC_24648922","title":"Synovial TGF-β1 and MMP-3 levels and their correlation with the progression of temporomandibular joint osteoarthritis combined with disc displacement: A preliminary study.","date":"2012","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/24648922","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23625833","id":"PMC_23625833","title":"NFATc3 promotes Ca(2+) -dependent MMP3 expression in astroglial cells.","date":"2013","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/23625833","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26829555","id":"PMC_26829555","title":"Leptin and Pro-Inflammatory Stimuli Synergistically Upregulate MMP-1 and MMP-3 Secretion in Human Gingival Fibroblasts.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26829555","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16919028","id":"PMC_16919028","title":"Expression of matrix metalloproteinases (MMP-2, MMP-3, and MMP-9) and fibronectin in lichen planus.","date":"2006","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16919028","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27108649","id":"PMC_27108649","title":"Knockdown of RHOC by shRNA suppresses invasion and migration of cholangiocellular carcinoma cells via inhibition of MMP2, MMP3, MMP9 and epithelial-mesenchymal transition.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/27108649","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20822909","id":"PMC_20822909","title":"The rs522616 polymorphism in the matrix metalloproteinase-3 (MMP-3) gene is associated with sporadic brain arteriovenous malformation in a Chinese population.","date":"2010","source":"Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia","url":"https://pubmed.ncbi.nlm.nih.gov/20822909","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37188676","id":"PMC_37188676","title":"IGF2BP3 promotes adult myocardial regeneration by stabilizing MMP3 mRNA through interaction with m6A modification.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37188676","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22848309","id":"PMC_22848309","title":"Expression of MMP-3 and TIMP-3 in gastric cancer tissue and its clinical significance.","date":"2011","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/22848309","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23146660","id":"PMC_23146660","title":"Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis.","date":"2012","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23146660","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26008967","id":"PMC_26008967","title":"MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26008967","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15708865","id":"PMC_15708865","title":"Latent cytokines: development of novel cleavage sites and kinetic analysis of their differential sensitivity to MMP-1 and MMP-3.","date":"2005","source":"Protein engineering, design & selection : PEDS","url":"https://pubmed.ncbi.nlm.nih.gov/15708865","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24946722","id":"PMC_24946722","title":"PLGF inhibition impairs metastasis of larynx carcinoma through MMP3 downregulation.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24946722","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18571835","id":"PMC_18571835","title":"AMF/PGI transactivates the MMP-3 gene through the activation of Src-RhoA-phosphatidylinositol 3-kinase signaling to induce hepatoma cell migration.","date":"2008","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/18571835","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30297859","id":"PMC_30297859","title":"Increased levels of circulating MMP3 correlate with severe rejection in face transplantation.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30297859","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34530193","id":"PMC_34530193","title":"Targeting matrix metalloproteinase MMP3 greatly enhances oncolytic virus mediated tumor therapy.","date":"2021","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34530193","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31809475","id":"PMC_31809475","title":"17β-Estradiol Prevents Extracellular Matrix Degradation by Downregulating MMP3 Expression via PI3K/Akt/FOXO3 Pathway.","date":"2020","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/31809475","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25457105","id":"PMC_25457105","title":"Genipin inhibits MMP-1 and MMP-3 release from TNF-a-stimulated human periodontal ligament cells.","date":"2014","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/25457105","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40311957","id":"PMC_40311957","title":"MMP3 at the crossroads: Linking molecular pathways to disease diagnosis and therapy.","date":"2025","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/40311957","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26057330","id":"PMC_26057330","title":"Cyclosporine A Downregulates MMP-3 and MMP-13 Expression in Cultured Pterygium Fibroblasts.","date":"2015","source":"Cornea","url":"https://pubmed.ncbi.nlm.nih.gov/26057330","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15610405","id":"PMC_15610405","title":"MMP-3 and -8 expression is found in the condylar surface of temporomandibular joints with internal derangement.","date":"2005","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15610405","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31377584","id":"PMC_31377584","title":"Cyclic tensile force-upregulated IL6 increases MMP3 expression by human periodontal ligament cells.","date":"2019","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/31377584","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20092902","id":"PMC_20092902","title":"Impact of ENPP1 and MMP3 gene polymorphisms on aortic calcification in patients with type 2 diabetes in a Korean population.","date":"2010","source":"Diabetes research and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/20092902","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33482178","id":"PMC_33482178","title":"MiR-874-3p plays a protective role in intervertebral disc degeneration by suppressing MMP2 and MMP3.","date":"2021","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33482178","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26191285","id":"PMC_26191285","title":"Gene polymorphism of IL-6 and MMP-3 decreases passive range of motion after rotator cuff repair.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26191285","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18640045","id":"PMC_18640045","title":"Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors.","date":"2008","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18640045","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21928379","id":"PMC_21928379","title":"Age-related expression of MCP-1 and MMP-3 in mouse intervertebral disc in relation to TWEAK and TNF-α stimulation.","date":"2011","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/21928379","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29172775","id":"PMC_29172775","title":"C/EBPβ Promotion of MMP3-Dependent Tumor Cell Invasion and Association with Metastasis in Colorectal Cancer.","date":"2017","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/29172775","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30755371","id":"PMC_30755371","title":"Are MMP3, MMP8 and TIMP2 gene variants associated with anterior cruciate ligament rupture susceptibility?","date":"2019","source":"Journal of science and medicine in sport","url":"https://pubmed.ncbi.nlm.nih.gov/30755371","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29670668","id":"PMC_29670668","title":"Association of Maternal and Fetal Single-Nucleotide Polymorphisms in Metalloproteinase (MMP1, MMP2, MMP3, and MMP9) Genes with Preeclampsia.","date":"2018","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/29670668","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30201492","id":"PMC_30201492","title":"IL-37 diminishes proteoglycan loss in human OA cartilage: donor-specific link between IL-37 and MMP-3.","date":"2018","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/30201492","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30412863","id":"PMC_30412863","title":"MMP-3 and MMP-8 in rat mandibular condylar cartilage associated with dietary loading, estrogen level, and aging.","date":"2018","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/30412863","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24799419","id":"PMC_24799419","title":"Functional Significance of MMP3 and TIMP2 Polymorphisms in Cleft Lip/Palate.","date":"2014","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/24799419","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37139985","id":"PMC_37139985","title":"Induction of MMP-3 and MMP-9 expression during Helicobacter pylori infection via MAPK signaling pathways.","date":"2023","source":"Helicobacter","url":"https://pubmed.ncbi.nlm.nih.gov/37139985","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35949513","id":"PMC_35949513","title":"New insights into the role of matrix metalloproteinase 3 (MMP3) in bone.","date":"2022","source":"FASEB bioAdvances","url":"https://pubmed.ncbi.nlm.nih.gov/35949513","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32589824","id":"PMC_32589824","title":"In vivo delivery of MMP3-shRNA and Sox9 lentivirus cocktail enhances matrix synthesis to prevent lumbar disc degeneration.","date":"2020","source":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","url":"https://pubmed.ncbi.nlm.nih.gov/32589824","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19342253","id":"PMC_19342253","title":"Role of a LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytes.","date":"2009","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/19342253","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17094476","id":"PMC_17094476","title":"Kinetics of MMP-1 and MMP-3 produced by mast cells and macrophages in liver fibrogenesis of rat.","date":"2006","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17094476","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17664256","id":"PMC_17664256","title":"Differential expression of the metalloproteinase MMP3 and the alpha5 integrin subunit in human myometrium at labour.","date":"2007","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/17664256","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31536594","id":"PMC_31536594","title":"ERK1/ATF-2 signaling axis contributes to interleukin-1β-induced MMP-3 expression in dermal fibroblasts.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31536594","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26656061","id":"PMC_26656061","title":"Association Between IL-6 and MMP3 Common Genetic Polymorphisms and Idiopathic Scoliosis in Bulgarian Patients: A Case-control Study.","date":"2016","source":"Spine","url":"https://pubmed.ncbi.nlm.nih.gov/26656061","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31486483","id":"PMC_31486483","title":"MiR-574-3p exerts as a tumor suppressor in ovarian cancer through inhibiting MMP3 expression.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31486483","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15782307","id":"PMC_15782307","title":"Dysregulation of renal MMP-3 and MMP-7 in canine X-linked Alport syndrome.","date":"2005","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/15782307","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36793308","id":"PMC_36793308","title":"METTL3 promotes SMSCs chondrogenic differentiation by targeting the MMP3, MMP13, and GATA3.","date":"2023","source":"Regenerative therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36793308","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28105338","id":"PMC_28105338","title":"Association between MMP-3 and MMP-9 polymorphisms and coronary artery disease.","date":"2016","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/28105338","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10419448","id":"PMC_10419448","title":"Matrix metalloproteinases.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10419448","citation_count":3561,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14718574","id":"PMC_14718574","title":"The human plasma proteome: a nonredundant list developed by combination of four separate sources.","date":"2004","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/14718574","citation_count":658,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9737711","id":"PMC_9737711","title":"Matrix metalloproteinases: structures, evolution, and diversification.","date":"1998","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/9737711","citation_count":612,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10947989","id":"PMC_10947989","title":"Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3.","date":"2000","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/10947989","citation_count":609,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477941","id":"PMC_12477941","title":"Prediction of the risk of myocardial infarction from polymorphisms in candidate genes.","date":"2002","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12477941","citation_count":531,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9288970","id":"PMC_9288970","title":"Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9288970","citation_count":499,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3030290","id":"PMC_3030290","title":"Comparison of human stromelysin and collagenase by cloning and sequence analysis.","date":"1986","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/3030290","citation_count":455,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12149192","id":"PMC_12149192","title":"Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12149192","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8662692","id":"PMC_8662692","title":"Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8662692","citation_count":418,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20385826","id":"PMC_20385826","title":"Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC).","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/20385826","citation_count":376,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2383557","id":"PMC_2383557","title":"Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate.","date":"1990","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2383557","citation_count":372,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3477804","id":"PMC_3477804","title":"Human skin fibroblast stromelysin: structure, glycosylation, substrate specificity, and differential expression in normal and tumorigenic cells.","date":"1987","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3477804","citation_count":361,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9148753","id":"PMC_9148753","title":"Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release.","date":"1997","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9148753","citation_count":353,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12009331","id":"PMC_12009331","title":"Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes.","date":"2002","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/12009331","citation_count":348,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11375993","id":"PMC_11375993","title":"Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin).","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11375993","citation_count":334,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8804434","id":"PMC_8804434","title":"Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8804434","citation_count":294,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15894268","id":"PMC_15894268","title":"MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.","date":"2005","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/15894268","citation_count":278,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7523391","id":"PMC_7523391","title":"Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7523391","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3360803","id":"PMC_3360803","title":"The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin.","date":"1988","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3360803","citation_count":236,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8535233","id":"PMC_8535233","title":"Stromelysin-1: three-dimensional structure of the inhibited catalytic domain and of the C-truncated proenzyme.","date":"1995","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/8535233","citation_count":234,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25217476","id":"PMC_25217476","title":"Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.","date":"2014","source":"Thorax","url":"https://pubmed.ncbi.nlm.nih.gov/25217476","citation_count":229,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52539,"output_tokens":7459,"usd":0.134751},"stage2":{"model":"claude-opus-4-6","input_tokens":11241,"output_tokens":3961,"usd":0.232845},"total_usd":0.793292,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":66332,"output_tokens":9887,"usd":0.173651},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14046,"output_tokens":3912,"usd":0.252045}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"MMP3/stromelysin-1 expression in phenotypically normal mammary epithelial cells is sufficient to promote epithelial-to-mesenchymal transition and drive mammary tumor initiation and malignant conversion in vivo; these effects are blocked by co-expression of TIMP1, placing MMP3 upstream of tumor initiation.\",\n      \"method\": \"Tetracycline-regulated transgenic mouse model, TIMP1 co-expression rescue experiment, genomic analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — in vivo gain-of-function with genetic rescue by TIMP1, replicated across multiple transgenic models in a highly cited foundational paper\",\n      \"pmids\": [\"10428026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MMP-3 specifically induces secondary and tertiary lateral ductal branching during mid-puberty and early pregnancy in mammary gland morphogenesis, as demonstrated by MMP-3 null mice which lack this branching pattern.\",\n      \"method\": \"Genetic knockout (Mmp3-null mice), pharmacological MMP inhibition, in vivo mammary gland analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific developmental phenotype, orthogonal pharmacological validation\",\n      \"pmids\": [\"12975354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MMP-3 mediates neuroinflammatory signaling in activated microglia: inhibition of MMP-3 suppresses LPS-induced NF-κB, AP-1, and MAPK activities as well as iNOS and pro-inflammatory cytokine expression; a cross-talk between ROS and MMP-3 was also identified.\",\n      \"method\": \"Pharmacological MMP inhibition in primary microglia and BV2 cells, N-acetylcysteine/DPI treatment, activity assays for NF-κB/AP-1/MAPK\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean inhibitor-based KD with defined inflammatory phenotype, single lab\",\n      \"pmids\": [\"18419763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERα signaling in osteoblasts upregulates MMP3 expression; MMP3 then cleaves and solubilizes membrane-bound FasL, and soluble FasL induces osteoclast apoptosis — establishing the ERα→MMP3→FasL cleavage→osteoclast apoptosis pathway in estrogen-mediated bone protection.\",\n      \"method\": \"siRNA knockdown of MMP3, selective MMP3 inhibitor, ERαKO mouse-derived osteoblasts, EGFP-FasL cleavage assay, conditioned media transfer, osteoblast-osteoclast co-culture\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal methods (siRNA, pharmacological inhibition, KO cells, functional coculture assay) in a single study\",\n      \"pmids\": [\"22927007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MMP-3 mediates psychosine-induced morphological transformation of microglia into multinucleated globoid cells; genetic ablation or chemical inhibition of MMP-3 prevents this transformation, and MMP-3 expression is elevated in the twitcher mouse model of Krabbe disease.\",\n      \"method\": \"Primary glial cultures with psychosine treatment, MMP-3 genetic knockout, chemical MMP-3 inhibition, twitcher mouse model, bone marrow transplantation\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — genetic KO and pharmacological inhibition both used with specific cellular phenotype, validated in disease model\",\n      \"pmids\": [\"23404611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Adiponectin increases MMP-3 expression in human chondrocytes through AdipoR1 (not AdipoR2), activating AMPK, p38, and NF-κB pathways; each pathway contributes to MMP-3 promoter activity.\",\n      \"method\": \"siRNA knockdown of AdipoR1/AdipoR2, kinase inhibitors (araA, compound C, SB203580, PDTC, TPCK), qPCR, Western blot, ELISA\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor-specific siRNA plus multiple pathway inhibitors, single lab\",\n      \"pmids\": [\"21321996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Activated STAT3 directly binds to the MMP3 promoter and transcriptionally regulates MMP3 in heme-treated brain microvascular endothelial cells, linking heme-induced STAT3 activation to MMP3-mediated endothelial apoptosis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), luciferase reporter assay for MMP3 promoter, JAK/STAT3 PCR arrays, qRT-PCR, Western blot, MTT/TUNEL apoptosis assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — ChIP and promoter reporter assay directly demonstrate STAT3 binding and transcriptional activation, single lab\",\n      \"pmids\": [\"23967200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NFATc3 transcriptionally drives Ca²⁺-dependent MMP3 expression in astrocytes via the calcineurin/NFAT pathway; constitutively active NFATc3 induces Mmp3, which is blocked by cyclosporin A, and this pathway is active in vivo in scar-forming astrocytes after brain injury.\",\n      \"method\": \"Constitutively active NFATc3 overexpression, cyclosporin A inhibition, calcium ionophore treatment, Mmp3 promoter luciferase reporter, stab-wound in vivo brain injury model, immunofluorescence\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1/2 — promoter reporter plus genetic gain-of-function and pharmacological inhibition, validated in vivo, single lab\",\n      \"pmids\": [\"23625833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MMP3 exposure induces Rac1b (a tumorigenic splice isoform of Rac1) expression in pancreatic cancer cells, increases cellular invasiveness, and activates tumorigenic transcriptional profiles; co-expression of MMP3 with activated KRAS in pancreatic acinar cells in transgenic mice stimulates metaplasia and immune cell infiltration.\",\n      \"method\": \"Recombinant MMP3 treatment of cultured pancreatic cancer cells, transgenic mouse co-expression model (MMP3 + activated KRAS), human tissue biopsy correlation, invasion assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro recombinant protein treatment plus in vivo transgenic model, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"24850902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Keratinocyte-expressed MMP3 promotes epidermal cell differentiation and impedes squamous cell carcinoma establishment; SP-1 cells stably expressing MMP3 lose tumor-forming capacity in immunocompromised mice, and differentiation-promoting effects are blocked by MMP3 inhibition.\",\n      \"method\": \"Keratinocyte-targeted MMP3 transgenic mice, stable MMP3 expression in SP-1 cell lines, orthotopic xenograft, broad-spectrum and selective MMP3 inhibitor, in vitro differentiation assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model plus pharmacological inhibition with defined cellular phenotype, single lab\",\n      \"pmids\": [\"18832569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MMP3 increases blood-brain barrier permeability by activating the ERK signaling pathway, which subsequently reduces tight junction (TJ) and VE-cadherin protein abundance in brain microvascular endothelial cells; MMP3-KO mice show reduced dye extravasation and increased TJ proteins.\",\n      \"method\": \"MMP3-knockout mice (in vivo dye extravasation, anesthesia assays), TEER and Transwell permeability assays in WT and MMP3-KO BMVECs, ERK inhibitor treatment, Western blot for TJ proteins\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO in vivo plus in vitro ERK inhibitor mechanistic dissection, single lab\",\n      \"pmids\": [\"33859779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MMP3 overexpression in adipose progenitor cells (APCs) inhibits adipocyte differentiation; recombinant MMP3 protein added to human preadipocytes inhibits differentiation, and this inhibition is attenuated by TIMP4 — establishing MMP3 as an anti-adipogenic factor whose activity is modulated by TIMP4.\",\n      \"method\": \"Mmp3 overexpression in 3T3-L1 preadipocytes, recombinant human MMP3 and TIMP4 protein treatment of primary human preadipocytes, MMP3 enzymatic activity assays, high-fat diet mouse model\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function overexpression plus recombinant protein treatment with rescue by TIMP4, single lab\",\n      \"pmids\": [\"27879248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF8 directly represses MMP3 transcription; IRF8 loss in tumor cells increases MMP3 expression and promotes tumor growth and spontaneous lung metastasis, effects that are significantly compromised by silencing MMP3 — identifying an IRF8-MMP3 transcriptional axis controlling tumor progression.\",\n      \"method\": \"Gene expression profiling, MMP3 siRNA knockdown, IRF8 stable silencing, orthotopic mouse mammary carcinoma model, luciferase reporter (MMP3 as direct transcriptional target)\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via double KD (IRF8 loss rescued by MMP3 KD) in vivo, supported by transcriptional evidence, single lab\",\n      \"pmids\": [\"26008967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NFAT1 directly transcriptionally activates MMP3 and IL8 in melanoma cells to promote tumor growth and lung metastasis; NFAT1 depletion reduces MMP3 expression, NFAT1 overexpression induces it, and restoration of NFAT1 rescues MMP3 to baseline levels.\",\n      \"method\": \"Stable NFAT1 silencing, microarray, NFAT1 overexpression, in vivo tumor growth and lung metastasis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct transcriptional target validated by gain- and loss-of-function with in vivo endpoint, single lab\",\n      \"pmids\": [\"27013197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BMAL1 deficiency enhances MMP3 transcription through activating NF-κB p65 phosphorylation; MMP3 is upregulated in mandibles of BMAL1-deficient mice and SMH patients, contributing to mandibular dysplasia.\",\n      \"method\": \"Bmal1-KO mice, RNA sequencing, protein chip analysis, p65 phosphorylation assays, SMH patient tissue analysis\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with mechanistic pathway (p65 phosphorylation) identified, validated in human patient tissue, single lab\",\n      \"pmids\": [\"29276151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP3 ablation in prostate cancer cells reduces in vitro growth with lowered AKT and ERK phosphorylation and decreased VEGFR1 and FGFR3 protein levels; in vivo, MMP3-ablated tumors grow slower and are less vascularized, and MMP3 in conditioned media supports endothelial tube formation.\",\n      \"method\": \"MMP3 shRNA ablation in prostate cancer cell lines, in vitro growth assays, in vivo tumor growth experiments, endothelial tube formation assay, Western blot for AKT/ERK phosphorylation and receptor levels\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined in vitro and in vivo phenotypes and pathway analysis, single lab\",\n      \"pmids\": [\"32896761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP3 knockout in tumor cells (CRISPR/Cas9) reduces tumoroid size, promotes necrosis within tumoroids, and reduces CD9 and CD63 tetraspanin levels in extracellular vesicles; MMP3-rich EVs from wild-type tumoroids rescue MMP3-KO tumoroid growth and restore MMP3/CD9/Ki-67 expression, demonstrating that EV-mediated MMP3 transfer promotes tumorigenesis.\",\n      \"method\": \"CRISPR/Cas9 MMP3 knockout, 3D tumoroid culture, EV isolation and transfer experiments, fluorescent protein-based EV tracking, Western blot for EV markers\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with rescue by EV transfer, multiple orthogonal readouts, single lab\",\n      \"pmids\": [\"32429403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of KMT2C or KMT2D drives upregulation of MMP3 via KDM6A-mediated epigenetic changes (altered H3K27me3); downregulation or pharmacological inhibition of KDM6A diminishes MMP3 upregulation and prevents brain metastasis similarly to direct MMP3 downregulation, establishing the KDM6A→MMP3 axis as a key mediator of KMT2C/D loss-driven TNBC metastasis.\",\n      \"method\": \"Kmt2c/Kmt2d knockout in murine TNBC models, global chromatin profiling (H3K4me1, H3K27ac, H3K27me3 ChIP-seq), KDM6A knockdown and pharmacological inhibition, Mmp3 KD, in vivo metastasis assays, human patient tissue analysis\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 — multiple orthogonal epigenomic and genetic approaches, validated in vivo, replicated in human patient data\",\n      \"pmids\": [\"38926506\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IGF2BP3 binds to MMP3 mRNA through interaction with N6-methyladenosine (m6A) modification and stabilizes it, increasing MMP3 protein expression; MMP3 acts downstream of IGF2BP3 to regulate cardiomyocyte proliferation and cardiac regeneration after myocardial infarction.\",\n      \"method\": \"IGF2BP3 gain- and loss-of-function in vitro and in vivo (mouse myocardial infarction model), m6A-RNA interaction assays, cardiomyocyte proliferation assays, cardiac function assessment\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic m6A-mRNA stabilization demonstrated with functional in vivo validation, single lab\",\n      \"pmids\": [\"37188676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AMF/PGI transactivates the MMP3 gene promoter through AP-1 via the Src-RhoA-PI3-kinase signaling pathway (these three molecules form a complex), and this enzymatic/signaling activity drives hepatoma cell migration.\",\n      \"method\": \"MMP-3 promoter-reporter assay (AP-1 binding), pathway inhibitors for Src/RhoA/PI3K, co-immunoprecipitation of Src-RhoA-PI3K complex, cell migration assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter reporter plus Co-IP of signaling complex plus functional migration assay, single lab\",\n      \"pmids\": [\"18571835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Stromelysin-1 (MMP-3) cleaves myelin basic protein (MBP), with the citrullinated charge isomer component-8 being more susceptible to cleavage than component-1; MMP-3 cleaves MBP even in the presence of lipids and within the context of myelin, releasing peptides including immunodominant epitopes.\",\n      \"method\": \"In vitro MBP cleavage assay with stromelysin-1, comparison of MBP charge isomers, cleavage in lipid/myelin context, peptide identification\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro enzymatic assay with substrate specificity analysis, single lab\",\n      \"pmids\": [\"16871440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MMP-3 activity and expression are elevated following LPS-induced dopaminergic neurodegeneration in the substantia nigra, and its downstream target CTGF expression increases temporally correlated with the neurodegenerative phase, suggesting MMP-3 acts upstream of CTGF in neuroinflammation-induced dopaminergic neurotoxicity.\",\n      \"method\": \"Direct LPS injection into substantia nigra of rats, Western blot for MMP-3 and CTGF at multiple time points, immunohistochemistry\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — correlative temporal expression in vivo model without direct mechanistic manipulation of MMP3\",\n      \"pmids\": [\"19463894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ERK1 (but not ERK2) activates ATF-2 phosphorylation in response to IL-1β, and the ERK1/ATF-2 signaling axis drives MMP-3 mRNA expression in dermal fibroblasts; ERK or ATF-2 siRNA knockdown reduces IL-1β-induced MMP-3 expression.\",\n      \"method\": \"siRNA knockdown of ERK1, ERK2, and ATF-2; ERK inhibitor FR180204; IL-1β stimulation; qRT-PCR for MMP-3 mRNA\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific siRNA knockdown dissecting ERK1 vs ERK2 roles in ATF-2 phosphorylation and MMP-3 induction, single lab\",\n      \"pmids\": [\"31536594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TNF-α stimulates MMP-3 production in cementoblasts partially via PGE2 (through Cox-2), and through combined NF-κB and p38 MAPK signaling; complete suppression of MMP-3 upregulation requires inhibiting both pathways simultaneously.\",\n      \"method\": \"Cox-2 inhibitor, PGE2 exogenous addition, NF-κB inhibitor, p38 MAPK inhibitor, qRT-PCR and ELISA in OCCM-30 cementoblast cell line\",\n      \"journal\": \"Archives of oral biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway inhibitors systematically dissected, PGE2 as intermediate confirmed by exogenous addition, single lab\",\n      \"pmids\": [\"25956994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A biallelic insertion/deletion polymorphism in the MMP3 promoter (5A/6A, at -1608 bp from transcription start) alters transcription factor binding and influences MMP3 mRNA and protein levels, contributing to arterial trait variation and coronary heart disease risk; the high-expression 5A allele has been under positive selection in Europeans.\",\n      \"method\": \"Phylogenetic and population genetic analysis of primate sequences, statistical tests of haplotype diversity and population differentiation, functional data on transcription factor binding\",\n      \"journal\": \"Current biology : CB\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — evolutionary/population genetic analysis combined with published functional data on promoter activity, single study\",\n      \"pmids\": [\"15341739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MMP3 promoter polymorphism rs522616 allele A creates a specific DNA-protein binding complex and shows greater promoter activity than the G allele; however, the effect of rs522616 is regulated by the rs3025058 allele background, demonstrating that these MMP3 promoter variants are functional and modulate transcription.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA) for DNA-protein binding, luciferase reporter assays for promoter activity of different allele combinations\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro promoter activity and DNA-protein interaction assays, single lab\",\n      \"pmids\": [\"24799419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Computational modeling of MMP-3 enzyme-substrate complexes indicates that substrate selectivity is dominated by the S1' pocket and S2/S3 region, and proposes a catalytic mechanism where the Zn-ion polarizes oxygens from the catalytic glutamate to form a nucleophile leading to a tetrahedral oxyanion anhydride transition state.\",\n      \"method\": \"Molecular dynamics simulations of MMP-3 with natural substrate (P4-P4' spanning), substrate docking into catalytic domain crystal structure\",\n      \"journal\": \"Journal of computer-aided molecular design\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational modeling without experimental validation\",\n      \"pmids\": [\"14713188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GBP5 promotes glioblastoma cell proliferation, migration, and invasion via the Src/ERK1/2/MMP3 signaling axis; GBP5 overexpression upregulates MMP3, and targeting GBP5 impairs tumor growth in vivo.\",\n      \"method\": \"GBP5 overexpression and RNA interference knockdown in GBM cell lines, in vivo mouse tumor model, pathway inhibitor analysis\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with in vivo validation and pathway placement via Src/ERK/MMP3 axis, single lab\",\n      \"pmids\": [\"33608513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"MMP3 knockout in mice significantly increases trabecular bone mass and protects against ovariectomy-induced bone loss by inhibiting bone resorption (not by affecting bone formation); MMP3 promoter polymorphisms are associated with MMP3 expression and bone mineral density in postmenopausal women.\",\n      \"method\": \"Mmp3 KO mice with ovariectomy model, microCT analysis of bone microarchitecture, bone resorption/formation parameter analysis, human cohort with promoter polymorphism and transfection experiments\",\n      \"journal\": \"FASEB bioAdvances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific bone resorption phenotype plus human promoter functional validation, single lab\",\n      \"pmids\": [\"35949513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"MMP-3-deficient mice show no proteoglycan or collagen II loss in intervertebral discs at 64 weeks, whereas wild-type mice show clear diffuse proteoglycan loss, demonstrating a direct role for MMP-3 in age-related intervertebral disc degeneration.\",\n      \"method\": \"MMP-3-deficient vs wild-type mice, Safranin-O staining, immunohistochemistry for proteoglycan and collagen II at multiple ages\",\n      \"journal\": \"Journal of orthopaedic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific tissue preservation phenotype, single lab\",\n      \"pmids\": [\"21928379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MMP-3 and MMP-7 mRNA transcripts and enzymatic activity (confirmed by casein zymography) are elevated in the renal cortex of dogs with X-linked Alport syndrome and colocalize in the interstitial space; MMP-3 and MMP-7 likely augment activation of MMP-2 and MMP-9 in this context.\",\n      \"method\": \"Immunohistochemistry, RT-PCR, casein zymography in canine X-linked Alport syndrome nephropsy samples\",\n      \"journal\": \"Pediatric nephrology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — enzymatic activity confirmed by zymography but no direct mechanistic manipulation of MMP-3\",\n      \"pmids\": [\"15782307\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MMP3 (stromelysin-1) is a secreted zinc-dependent matrix metalloproteinase that degrades multiple extracellular matrix components and activates other MMPs; it is transcriptionally regulated by diverse upstream factors including STAT3, NFATc3, NFAT1, IRF8 (repressor), BMAL1/NF-κB, KDM6A (epigenetic), and ERK1/ATF-2 signaling downstream of cytokines (IL-1β, TNF-α) and growth factors; it drives mammary tumor initiation and EMT, induces lateral mammary ductal branching, cleaves FasL to trigger osteoclast apoptosis downstream of ERα signaling, promotes Rac1b-mediated pancreatic cancer invasiveness, mediates microglial globoid cell formation in Krabbe disease, increases blood-brain barrier permeability via ERK signaling, is stabilized post-transcriptionally by IGF2BP3 through m6A-mRNA interaction, and its promoter activity is functionally modulated by 5A/6A and other polymorphisms.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"MMP3 (stromelysin-1) was cloned and its cDNA-derived amino acid sequence determined, revealing it is secreted as a proenzyme with a putative zinc-binding site homologous to thermolysin, and identified as the human ortholog of rat transin.\",\n      \"method\": \"cDNA cloning and sequence analysis\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original sequence determination, foundational molecular characterization, highly cited\",\n      \"pmids\": [\"3030290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1987,\n      \"finding\": \"Human stromelysin (MMP3) was purified and shown to degrade proteoglycan, fibronectin, laminin, and type IV collagen but not interstitial type I collagen; it is synthesized as a preproenzyme (53,977 Da) and secreted as glycosylated and non-glycosylated proforms; trypsin activation removes 84 amino acids from the N-terminus generating the 45-kDa active enzyme.\",\n      \"method\": \"Protein purification, substrate cleavage assays, N-terminal sequencing, SDS-PAGE, glycosylation analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purification with direct substrate assays and biochemical characterization, foundational paper\",\n      \"pmids\": [\"3477804\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The complete primary structure of human MMP-3 (477 residues, 17-residue signal peptide) was determined, confirming identity with stromelysin; MMP-3 and collagenase share 54% sequence identity suggesting common evolutionary origin; IL-1β rapidly induces MMP-3 mRNA in synovial fibroblasts, and retinoic acid or dexamethasone suppresses it.\",\n      \"method\": \"cDNA sequencing, Northern blot, cytokine/hormone treatment of synovial fibroblast cultures\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete primary structure determination with functional gene regulation experiments\",\n      \"pmids\": [\"3360803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"ProMMP-3 activation proceeds through a stepwise mechanism: serine proteinases (neutrophil elastase, plasmin, kallikrein, chymotrypsin) cleave the propeptide at different sites to generate intermediate forms (~53 kDa), which then undergo bimolecular autolytic processing to the fully active 45-kDa species; APMA activates via an intramolecular cleavage at Glu68-Val69 to an intermediate that is then converted by intermolecular reaction; MMP-3 itself cannot activate proMMP-3.\",\n      \"method\": \"Kinetic analysis, N-terminal sequencing of activation intermediates, in vitro proteinase incubation assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — detailed kinetic and sequence analysis of activation mechanism, foundational biochemistry paper\",\n      \"pmids\": [\"2383557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"MMP-3 (along with MMP-1 and MMP-2) produced by human dermal fibroblasts degrades insulin-like growth factor binding protein-3 (IGFBP-3) in vitro, with cleavage sites identified in the mid-region of IGFBP-3, potentially enhancing IGF bioavailability.\",\n      \"method\": \"IGFBP-3 substrate zymography, immunoaffinity depletion, in vitro cleavage assays with purified MMPs, cleavage site sequencing\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified enzyme, defined substrates, cleavage site identification\",\n      \"pmids\": [\"7523391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Crystal structure of the inhibited catalytic domain and C-truncated proenzyme of stromelysin-1 (MMP-3) was determined by X-ray crystallography; the prodomain forms a separate folding unit with three α-helices and an extended peptide occupying the active site in the reverse direction compared to inhibitors; the catalytic core is similar to collagenases and thermolysin.\",\n      \"method\": \"X-ray crystallography\",\n      \"journal\": \"Protein science : a publication of the Protein Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure determination, foundational structural biology\",\n      \"pmids\": [\"8535233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"A common 5A/6A polymorphism in the MMP3 promoter (1608 bp from transcription start site) differentially binds nuclear proteins and regulates transcription: the 6A allele binds nuclear protein(s) more readily and drives lower reporter gene expression than 5A; this polymorphism is associated with progression of coronary atherosclerosis.\",\n      \"method\": \"Transient transfection reporter assays (CAT), EMSA, DNase I footprinting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (transfection + EMSA + footprinting) in one study defining functional promoter variant\",\n      \"pmids\": [\"8662692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Crystal structure of the MMP-3 catalytic domain in complex with TIMP-1 was solved; TIMP-1 adopts an elongated wedge shape and occupies the entire active-site cleft of MMP-3 along its long edge; Cys1 of TIMP-1 bidentately coordinates the catalytic zinc and Thr2 extends into the S1' specificity pocket, defining the mechanism of MMP-3 inhibition by TIMP-1.\",\n      \"method\": \"X-ray crystallography of MMP-3/TIMP-1 complex\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure of enzyme-inhibitor complex, foundational\",\n      \"pmids\": [\"9288970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"MMP-3 (along with MMP-2 and MMP-7) degrades decorin (DCN) at identified cleavage sites (including Leu211-Lys in the core protein); MMP-3 and MMP-2 cleave DCN in a similar pattern generating seven major fragments; digestion of a DCN-TGF-β1 complex by MMP-3 releases TGF-β1, suggesting MMPs can liberate ECM-sequestered growth factors.\",\n      \"method\": \"In vitro cleavage assays with purified MMPs, N-terminal sequencing of fragments, kinetic analysis (Km determination), TGF-β1 release assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified enzyme, identified substrates and cleavage sites, kinetics, TGF-β1 release measured\",\n      \"pmids\": [\"9148753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Transgenic expression of MMP3/stromelysin-1 in phenotypically normal mammary epithelial cells induces formation of invasive mesenchymal-like tumors in vivo; MMP3 promotes spontaneous premalignant changes and malignant conversion in mammary glands of transgenic mice; these effects are blocked by co-expression of a TIMP1 transgene, establishing MMP3 as a driver of tumor initiation.\",\n      \"method\": \"Tetracycline-regulated transgenic mouse model, TIMP1 co-transgenic rescue, histopathology, genomic analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with genetic rescue by TIMP1, replicated in multiple mouse models\",\n      \"pmids\": [\"10428026\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"MMP3 is a broad-spectrum matrix metalloproteinase with established roles in ECM degradation; key mechanistic features include a prodomain/cysteine-switch mechanism, zinc-dependent catalysis, activation by multiple proteinases, and inhibition by TIMPs.\",\n      \"method\": \"Review synthesizing biochemical, structural, and cell biology data\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — synthesis of replicated biochemical findings across multiple labs\",\n      \"pmids\": [\"10419448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"MMP-3 (stromelysin-1) cleaves MCP-1, MCP-2, and MCP-4 (monocyte chemoattractant proteins) between residues 4 and 5; the truncated products act as CC chemokine receptor antagonists lacking chemoattractant activity, demonstrating that MMP-3 can modulate inflammatory responses by inactivating chemokines.\",\n      \"method\": \"In vitro cleavage assays with recombinant MMPs, N-terminal sequencing, receptor binding, calcium flux, chemotaxis assays, in vivo carrageenan inflammation model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified enzyme with substrate identification, cleavage site mapping, in vitro functional assays and in vivo validation\",\n      \"pmids\": [\"12149192\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Osteopontin (OPN) is a novel substrate for MMP-3; three cleavage sites were identified in human OPN (Gly166-Leu167, Ala201-Tyr202, Asp210-Leu211); MMP-3 cleavage of OPN potentiates its function as an adhesive and migratory stimulus through cell-surface integrins, demonstrating that MMP-3 can enhance OPN bioactivity rather than simply degrade it.\",\n      \"method\": \"In vitro cleavage assays with purified MMP-3, cleavage site sequencing, cell adhesion and migration assays with integrin involvement, in vivo tissue evidence\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified enzyme, identified cleavage sites, functional consequences tested with cell assays\",\n      \"pmids\": [\"11375993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IL-1-induced MMP-3 expression in articular chondrocytes requires activation of ERK, p38, and JNK MAPK pathways, as well as AP-1 and NF-κB transcription factors; pathway-selective inhibitors each partially suppress MMP-3 induction, indicating convergent multi-pathway regulation.\",\n      \"method\": \"Pharmacological inhibition of MAPK pathways (PD98059, U0126, SB203580, curcumin, PDTC) with RT-PCR and protein readouts in human and bovine chondrocytes\",\n      \"journal\": \"Matrix biology : journal of the International Society for Matrix Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal inhibitors across two species, replicated findings\",\n      \"pmids\": [\"12009331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MMP-3 induces secondary and tertiary lateral branching of mammary ducts during mid-puberty and early pregnancy; genetic knockout of MMP-3 impairs this branching, while MMP-2 has distinct roles (inhibiting apoptosis to facilitate terminal end bud invasion and repressing precocious lateral branching), demonstrating site-specific functions of different MMPs in mammary morphogenesis.\",\n      \"method\": \"Pharmacological inhibition and genetic knockout mouse models (MMP-3 KO, MMP-2 KO, MMP-9 KO), mammary gland whole-mount analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with specific morphological phenotype, complemented by pharmacological approach\",\n      \"pmids\": [\"12975354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Molecular dynamics modeling of MMP-3 in complex with substrate peptides reveals that substrate adopts an antiparallel β-sheet conformation on the P-side; primary substrate selectivity is dominated by sidechains in the S1' pocket and the S2/S3 region (largely hydrophobic); a novel catalytic mechanism is proposed whereby the Zn-ion polarizes the oxygens of the catalytic glutamate to form a nucleophile leading to a tetrahedral oxyanion anhydride transition state.\",\n      \"method\": \"Molecular dynamics simulations and computational modeling of enzyme-substrate complexes\",\n      \"journal\": \"Journal of computer-aided molecular design\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational modeling only, no experimental validation in this paper\",\n      \"pmids\": [\"14713188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MMP-3 cleaves myelin basic protein (MBP), with the citrullinated charge isomer (component-8) being more susceptible to stromelysin-1 cleavage than component-1; cleavage occurs in the presence of lipids and within the context of intact myelin, releasing peptides containing the immunodominant epitope; differences in cleavage rate reflect conformational differences due to post-translational modifications.\",\n      \"method\": \"In vitro cleavage assays with purified stromelysin-1 and MBP charge isomers, presence of lipids/myelin, peptide fragment identification\",\n      \"journal\": \"Neurochemical research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with substrate variant comparison, single study\",\n      \"pmids\": [\"16871440\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MMP-3 cleaved MCP-3 at the N-terminus, generating a truncated form that binds CC-chemokine receptors 1, 2, and 3 but does not induce calcium fluxes or chemotaxis, instead acting as a general chemokine antagonist that dampens inflammation in vivo.\",\n      \"method\": \"In vitro cleavage assays with purified MMP-3, receptor binding assays, calcium flux measurements, in vivo inflammatory model\",\n      \"journal\": \"Science (New York, N.Y.)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — purified enzyme with substrate, cleavage site defined, in vitro functional readouts confirmed in vivo\",\n      \"pmids\": [\"10947989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"MMP-3 activity was optimized by developing engineered cleavage sites in a latent cytokine (LAP-mIFNβ) construct; kinetic parameters (kcat/Km) for MMP-1 and MMP-3 cleavage of 15 different linkers were measured by ELISA; introduction of the furin cleavage site-derived hydrophilic sequence increased MMP-3 sensitivity up to 29-fold, establishing substrate design rules for MMP-3 selectivity.\",\n      \"method\": \"In vitro ELISA-based kinetic assays with purified MMP-1 and MMP-3 against engineered substrates\",\n      \"journal\": \"Protein engineering, design & selection : PEDS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — kinetic characterization of substrate cleavage, single study, applied context\",\n      \"pmids\": [\"15708865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MMP-3 inhibition in LPS-stimulated microglia suppresses expression of iNOS and pro-inflammatory cytokines (TNF-α), and reduces activities of NF-κB, AP-1, and MAPK; reactive oxygen species (ROS) act upstream of MMP-3 induction, and MMP-3 inhibition also suppresses ROS production, revealing a bidirectional cross-talk between ROS and MMP-3 in microglial inflammatory signaling.\",\n      \"method\": \"Pharmacological inhibition of MMP-3 and MMP-9, ROS inhibition (NAC, DPI), NF-κB/AP-1/MAPK activity assays in primary microglia and BV2 cells\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — pharmacological inhibition with multiple pathway readouts, single study\",\n      \"pmids\": [\"18419763\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AMF/PGI (autocrine motility factor/phosphoglucose isomerase) transactivates the MMP-3 gene promoter through AP-1; this transactivation requires AMF/PGI enzymatic activity and proceeds via stimulation of Src-RhoA-PI3K signaling, with these three molecules forming a complex; the pathway links AMF/PGI-induced MMP-3 expression to hepatoma cell migration.\",\n      \"method\": \"MMP-3 promoter reporter assays, dominant-negative and pharmacological inhibitors of Src/RhoA/PI3K, co-immunoprecipitation showing Src-RhoA-PI3K complex, migration assays\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reporter assay + co-IP + functional migration assay, single lab\",\n      \"pmids\": [\"18571835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Adiponectin increases MMP-3 secretion in human chondrocytes through AdipoR1 (not AdipoR2) signaling; downstream pathway involves sequential activation of AMPK, p38, and NF-κB, all of which are required for adiponectin-induced MMP-3 promoter activation.\",\n      \"method\": \"siRNA knockdown of AdipoR1/R2, pharmacological inhibitors of AMPK (araA, compound C), p38 (SB203580), and NF-κB (PDTC, TPCK); qPCR, Western blot, ELISA; NF-κB promoter activity assays in human chondrocytes\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA + pharmacological inhibitors with multiple pathway readouts, single lab\",\n      \"pmids\": [\"21321996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"17β-Estradiol (E2) upregulates MMP3 expression in osteoblasts via ERα signaling; MMP3 then cleaves and solubilizes osteoblast-expressed FasL, generating soluble FasL that induces osteoclast apoptosis; specific MMP3 inhibition or MMP3 siRNA blocks FasL cleavage and preserves osteoclast survival, defining a molecular mechanism for estrogen's bone-protective effects.\",\n      \"method\": \"EGFP-FasL cleavage fluorescence assay, MMP3-specific inhibitor, MMP3 siRNA, ERαKO mouse osteoblasts, calvarial organ cultures, conditioned media transfer to osteoclast-osteoblast co-cultures\",\n      \"journal\": \"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods (fluorescent reporter, siRNA, KO mice, inhibitor), defined substrate (FasL), functional apoptosis readout\",\n      \"pmids\": [\"22927007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Phosphorylated STAT3 binds directly to the MMP3 promoter in heme-treated human brain microvascular endothelial cells and transcriptionally activates MMP3 expression; heme-induced MMP3 upregulation via STAT3 promotes endothelial cell apoptosis.\",\n      \"method\": \"ChIP assay, luciferase reporter assay with human MMP3 promoter, qRT-PCR, Western blot, MTT and TUNEL apoptosis assays, RT² Profile PCR arrays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + reporter assay + functional apoptosis readout, single lab\",\n      \"pmids\": [\"23967200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MMP-3 mediates psychosine-induced globoid cell (multinucleated microglia) formation; exposure to psychosine induces MMP-3 expression in primary glial cultures, and genetic ablation or chemical inhibition of MMP-3 prevents the morphological transformation of microglia into globoid cells; this effect is microglia-specific, not seen in peripheral macrophages.\",\n      \"method\": \"Primary glial cultures, MMP-3 knockout mice, pharmacological MMP-3 inhibition, psychosine treatment, twitcher mouse model, bone marrow transplantation\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO + chemical inhibition with specific cellular phenotype in primary cultures and disease model\",\n      \"pmids\": [\"23404611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"NFATc3 is a transcriptional activator of Mmp3 in astrocytes; constitutively active NFATc3 overexpression induces Mmp3 mRNA and protein selectively (not other MMPs or TIMPs); calcium ionophore and ATP-induced Mmp3 upregulation is blocked by the calcineurin inhibitor cyclosporin A and by actinomycin D; a Mmp3 promoter reporter is activated by increased intracellular calcium; in vivo, MMP3 is expressed in NFATc3-positive scar-forming astrocytes after brain injury.\",\n      \"method\": \"Constitutively active NFATc3 overexpression, calcium ionophore/BzATP treatment, CsA inhibition, Mmp3 promoter luciferase reporter, pure astrocyte cultures from neural stem cells, in vivo stab-wound model\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (OE, pharmacological inhibition, reporter assay, in vivo), replicated in pure astrocyte system\",\n      \"pmids\": [\"23625833\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"MMP3 stimulates expression of Rac1b (a tumorigenic splice isoform of Rac1) in pancreatic cancer cells; recombinant MMP3 treatment increases cellular invasiveness and activates tumorigenic transcriptional profiles; in transgenic mice, co-expression of MMP3 with activated KRAS in pancreatic acinar cells stimulates metaplasia and immune cell infiltration, priming the tumor microenvironment.\",\n      \"method\": \"Human PDA tissue biopsy analysis, transgenic mouse models (MMP3 + KRAS co-expression), recombinant MMP3 treatment of cultured pancreatic cancer cells, invasion assays\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic in vivo model + recombinant protein treatment + patient tissue validation\",\n      \"pmids\": [\"24850902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF8 directly represses MMP3 transcription; IRF8-loss leads to elevated MMP3 expression; silencing MMP3 in IRF8-null tumor cells significantly reduces their growth advantage and decreases spontaneous lung metastasis in an orthotopic mammary carcinoma model, defining an IRF8-MMP3 transcriptional axis in tumor progression.\",\n      \"method\": \"Gene expression profiling, MMP3 silencing in IRF8-null cells, orthotopic mouse mammary tumor model, lung metastasis quantification\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined in vivo phenotype, single lab\",\n      \"pmids\": [\"26008967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NFAT1 (NFATC2) directly regulates MMP3 transcription in melanoma; NFAT1 depletion reduces MMP3 expression, while NFAT1 overexpression induces it; restoration of NFAT1 recovers MMP3 levels; in vivo, MMP3 promotes melanoma tumor growth and lung metastasis downstream of NFAT1.\",\n      \"method\": \"Stable NFAT1 silencing, microarray, restoration experiments, in vivo tumor growth and metastasis assays\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with in vivo validation, single lab\",\n      \"pmids\": [\"27013197\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"MMP3 acts as an antiadipogenic factor in adipose progenitor cells (APCs); MMP3 enzymatic activity inhibits differentiation of 3T3-L1 preadipocytes and primary human preadipocytes; TIMP4 attenuates the inhibitory effect of MMP3 on adipogenesis; HFD-induced obesity downregulates APC MMP3 to trigger adipogenesis in a sex- and depot-dependent manner.\",\n      \"method\": \"Overexpression of Mmp3 in 3T3-L1 preadipocytes, recombinant human MMP3 and TIMP4 treatment of primary human preadipocytes, differentiation assays, HFD mouse model\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — recombinant protein treatment with functional differentiation readout, in vivo validation in mouse model\",\n      \"pmids\": [\"27879248\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BMAL1 deficiency upregulates MMP3 expression through activation of p65 (NF-κB) phosphorylation; in BMAL1-deficient mice, Mmp3 is upregulated throughout growth period; MMP3 upregulation contributes to mandibular dysplasia (skeletal mandibular hypoplasia), linking the circadian clock component BMAL1 to MMP3-mediated craniofacial development.\",\n      \"method\": \"RNA sequencing, protein chip analysis, Bmal1 KO mice, NF-κB phosphorylation analysis, human patient samples\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO model with defined molecular mechanism (p65 phosphorylation), human correlation\",\n      \"pmids\": [\"29276151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IL-1β-induced MMP-3 expression in dermal fibroblasts requires ERK1 (not ERK2) to phosphorylate ATF-2, which then transcriptionally activates MMP-3; ERK inhibition abolishes ATF-2 phosphorylation and MMP-3 induction; ERK1 siRNA but not ERK2 siRNA reduces ATF-2 phosphorylation, revealing an ERK1/ATF-2 axis specific to MMP-3 expression.\",\n      \"method\": \"siRNA knockdown of ERK1 and ERK2 separately, ATF-2 siRNA, ATF-2 inhibitor (SBI-0087702), ERK inhibitor (FR180204), Western blot of phosphorylation, RT-PCR of MMP-3 mRNA in dermal fibroblasts\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific siRNA distinguishing ERK1 vs ERK2, multiple inhibitors, single lab\",\n      \"pmids\": [\"31536594\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP3 knockout in tumor cells (CRISPR/Cas9) reduces tumoroid size, promotes necrotic areas within tumoroids, and results in additional release of broken extracellular vesicles; MMP3-rich EVs from wild-type tumoroids deeply penetrate MMP3-KO tumoroids and rescue proliferation and tumorigenesis, demonstrating that MMP3 can be transferred via EVs to regulate tumor growth.\",\n      \"method\": \"CRISPR/Cas9 MMP3 KO, 3D tumoroid culture, EV isolation and characterization (NanoSight), fluorescent EV tracking, conditioned medium rescue experiments, Ki-67 staining\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR KO with EV rescue experiment, novel mechanism, single lab\",\n      \"pmids\": [\"32429403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MMP-3 ablation in prostate cancer cells reduces AKT and ERK phosphorylation and total VEGFR1 and FGFR3 protein levels, decreasing intrinsic cell growth; tumor-derived MMP-3 also promotes angiogenesis extrinsically, as MMP-3-ablated conditioned media slows endothelial tube formation; in vivo MMP-3-ablated tumors grow slower and are less vascularized.\",\n      \"method\": \"MMP-3 siRNA ablation in prostate cancer cell lines, in vitro growth assays, Western blot for AKT/ERK/VEGFR1/FGFR3, endothelial tube formation assays with conditioned media, in vivo tumor growth and vascularization\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with in vitro and in vivo validation, multiple pathway readouts, single lab\",\n      \"pmids\": [\"32896761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"MMP3 deficiency (KO mice or MMP3 inhibition) increases blood-brain barrier integrity by preserving tight junction (TJ) and VE-cadherin proteins; conversely, MMP3 upregulation reduces TJ and VE-cadherin abundance in brain microvascular endothelial cells; the effect requires ERK signaling, as an ERK inhibitor blocks MMP3-mediated reduction of TJ proteins; MMP3-KO mice show reduced dye extravasation and altered anesthesia kinetics consistent with improved BBB function.\",\n      \"method\": \"MMP3 KO mice, TEER and Transwell barrier assays, dye extravasation in vivo, TJ/VE-cadherin Western blot, ERK inhibitor treatment\",\n      \"journal\": \"Oxidative medicine and cellular longevity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO + inhibitor + in vivo and in vitro barrier assays, ERK pathway mechanistically linked, single lab\",\n      \"pmids\": [\"33859779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GBP5 promotes glioblastoma aggressiveness through activation of the Src/ERK1/2/MMP3 axis; GBP5 overexpression increases MMP3, and silencing GBP5 reduces MMP3-dependent proliferation, migration, and invasion in vitro and impairs tumor growth in vivo.\",\n      \"method\": \"GBP5 overexpression and siRNA knockdown in GBM cell lines, in vitro migration/invasion/proliferation assays, in vivo tumor implantation, Src/ERK1/2 pathway inhibitors\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with in vivo validation, pathway inhibitors used, single lab\",\n      \"pmids\": [\"33608513\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IGF2BP3 binds and stabilizes MMP3 mRNA through interaction with N6-methyladenosine (m6A) modification; IGF2BP3 promotes cardiomyocyte proliferation and cardiac regeneration after myocardial infarction; MMP3 acts downstream of IGF2BP3 to regulate cardiomyocyte proliferation, as functional analyses of MMP3 itself show it mediates this regenerative effect.\",\n      \"method\": \"Gain- and loss-of-function of IGF2BP3 in vitro and in vivo (mouse MI model), RIP assay showing IGF2BP3-MMP3 mRNA interaction, m6A modification analysis, MMP3 functional assays in cardiomyocytes\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — RIP demonstrates mRNA-protein interaction, gain/loss-of-function in vivo, novel post-transcriptional mechanism, single lab\",\n      \"pmids\": [\"37188676\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Loss of histone methyltransferases KMT2C or KMT2D drives brain metastasis in triple-negative breast cancer via KDM6A-dependent upregulation of MMP3; global chromatin profiling showed altered H3K4me1, H3K27ac, and H3K27me3 marks in KO cells; KDM6A binding at the Mmp3 locus correlates with its increased expression; pharmacological inhibition of KDM6A or direct Mmp3 knockdown prevents brain metastasis equivalently.\",\n      \"method\": \"Kmt2c/Kmt2d KO mouse models, ChIP-seq (H3K4me1, H3K27ac, H3K27me3, KDM6A), RNA-seq, KDM6A inhibition, Mmp3 shRNA, in vivo brain metastasis assays, human KMT2C-mutant TNBC patient samples\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multi-omic chromatin profiling + genetic KO + pharmacological inhibition + in vivo validation + human patient correlation\",\n      \"pmids\": [\"38926506\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MMP3 (stromelysin-1) is a secreted zinc-dependent endopeptidase that is synthesized as a proenzyme activated stepwise by serine proteinases and autocatalytic intermolecular cleavage; its crystal structure reveals a catalytic zinc coordinated by TIMP-1's Cys1 for inhibition and a S1' specificity pocket governing substrate selectivity; MMP3 degrades a broad range of ECM substrates (proteoglycan, fibronectin, laminin, type IV collagen, decorin, IGFBP-3, osteopontin, myelin basic protein) and cleaves chemokines (MCP-1/2/3/4) to generate receptor antagonists that dampen inflammation; transcriptionally, MMP3 is induced by IL-1β, TNF-α, and adiponectin through convergent MAPK (ERK, p38, JNK), NF-κB, and AP-1 pathways, with the ERK1/ATF-2 axis specifically required in fibroblasts, NFAT1/NFATc3 mediating Ca²⁺-dependent induction in T cells and astrocytes, and STAT3 directly binding its promoter in endothelial cells; the 5A/6A promoter polymorphism alters transcription factor binding and MMP3 expression levels; MMP3 drives epithelial-to-mesenchymal transition and tumor initiation, activates Rac1b signaling in pancreatic cancer, cleaves FasL to solubilize it and promote osteoclast apoptosis downstream of estrogen/ERα signaling, increases blood-brain barrier permeability via ERK-dependent TJ protein degradation, and its mRNA stability is post-transcriptionally regulated by IGF2BP3 through m6A recognition; epigenetically, KMT2C/D loss upregulates MMP3 through KDM6A-mediated H3K27me3 demethylation, driving brain metastasis.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"MMP3 (stromelysin-1) is a secreted zinc-dependent matrix metalloproteinase that degrades multiple extracellular matrix substrates—including proteoglycans, collagens, and myelin basic protein—and functions broadly in tissue remodeling, morphogenesis, inflammation, and tumor progression [PMID:16871440, PMID:21928379, PMID:12975354]. In mammary epithelium, MMP3 is sufficient to initiate epithelial-to-mesenchymal transition and malignant conversion in a TIMP1-inhibitable manner, drives lateral ductal branching during development, and promotes metastasis downstream of KDM6A-mediated epigenetic derepression or NFAT1 transcriptional activation [PMID:10428026, PMID:12975354, PMID:38926506, PMID:27013197]. MMP3 cleaves membrane-bound FasL to generate soluble FasL that induces osteoclast apoptosis downstream of ERα signaling, and MMP3-knockout mice exhibit increased trabecular bone mass and resistance to ovariectomy-induced bone loss [PMID:22927007, PMID:35949513]. MMP3 transcription is regulated by STAT3, NFATc3, NFAT1, IRF8 (repressor), BMAL1/NF-κB, and ERK1/ATF-2 signaling, and its mRNA is post-transcriptionally stabilized by IGF2BP3 through m6A recognition [PMID:23967200, PMID:23625833, PMID:26008967, PMID:29276151, PMID:31536594, PMID:37188676].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"The question of whether MMP3 is merely a matrix-degrading enzyme or can drive tumor initiation was resolved when autoactivated MMP3 expression in normal mammary epithelium proved sufficient to induce EMT, genomic instability, and malignant conversion, all blocked by TIMP1 co-expression.\",\n      \"evidence\": \"Tet-regulated MMP3 transgenic mice with TIMP1 rescue, genomic analysis of resulting tumors\",\n      \"pmids\": [\"10428026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of direct MMP3 substrates responsible for EMT induction unknown\", \"Whether MMP3-driven EMT requires catalytic activity vs. non-catalytic signaling not tested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"The physiological developmental function of MMP3 was established when Mmp3-null mice revealed a specific requirement for MMP3 in secondary and tertiary lateral mammary ductal branching during puberty and early pregnancy.\",\n      \"evidence\": \"Mmp3-knockout mice with mammary gland morphometric analysis, pharmacological MMP inhibition\",\n      \"pmids\": [\"12975354\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream substrates mediating branching morphogenesis not identified\", \"Relationship between branching function and tumor-promoting function unclear\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"The question of whether MMP3 expression varies functionally across human populations was addressed by identifying a 5A/6A promoter polymorphism under positive selection that modulates transcription factor binding and MMP3 expression levels.\",\n      \"evidence\": \"Phylogenetic analysis of primate sequences, population genetics, published functional promoter data\",\n      \"pmids\": [\"15341739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific transcription factors differentially binding 5A vs 6A alleles not fully identified\", \"Causal relationship to coronary heart disease requires Mendelian randomization\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"MMP3's substrate repertoire was expanded beyond classical ECM components when it was shown to cleave myelin basic protein, with preference for citrullinated MBP even within intact myelin, releasing immunodominant peptide epitopes relevant to demyelinating disease.\",\n      \"evidence\": \"In vitro cleavage assays comparing MBP charge isomers in lipid/myelin contexts\",\n      \"pmids\": [\"16871440\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of MMP3-mediated MBP cleavage in demyelination not demonstrated\", \"Kinetic parameters relative to other MBP-cleaving enzymes not compared\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"MMP3 was positioned as a mediator of neuroinflammatory signaling when its inhibition suppressed LPS-induced NF-κB, AP-1, and MAPK activation in microglia, and separately, MMP3 was shown to promote keratinocyte differentiation and suppress squamous cell carcinoma formation, revealing context-dependent pro- versus anti-tumorigenic roles.\",\n      \"evidence\": \"Pharmacological MMP3 inhibition in microglia with pathway readouts; keratinocyte-targeted MMP3 transgenic mice and SP-1 xenograft model\",\n      \"pmids\": [\"18419763\", \"18832569\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MMP3's anti-tumorigenic effect in squamous epithelia operates through the same substrates as its pro-tumorigenic mammary role is unknown\", \"Direct substrates mediating microglial inflammatory signaling not identified\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"MMP3's role in age-related tissue degeneration was demonstrated when Mmp3-deficient mice were protected from intervertebral disc proteoglycan and collagen II loss at 64 weeks, establishing MMP3 as a driver of disc matrix degradation.\",\n      \"evidence\": \"Mmp3-knockout vs wild-type mice, Safranin-O and immunohistochemistry at multiple time points\",\n      \"pmids\": [\"21928379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MMP3 acts directly on disc proteoglycans or through activation of other MMPs not determined\", \"Contribution relative to other disc-expressed MMPs unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Multiple transcription factors were shown to directly control MMP3 transcription in a cell-type-specific manner: STAT3 binds the MMP3 promoter in heme-stimulated endothelial cells, NFATc3 drives MMP3 via calcineurin/NFAT signaling in astrocytes after brain injury, and ERα signaling upregulates MMP3 in osteoblasts where it cleaves FasL to trigger osteoclast apoptosis.\",\n      \"evidence\": \"ChIP and promoter-reporter for STAT3; constitutively active NFATc3 plus cyclosporin A inhibition with in vivo stab-wound model; siRNA/inhibitor of MMP3 in osteoblasts with FasL cleavage assay and osteoblast-osteoclast co-culture\",\n      \"pmids\": [\"23967200\", \"23625833\", \"22927007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT3, NFATc3, and ERα pathways converge on common promoter elements not resolved\", \"Structural basis for FasL cleavage by MMP3 not determined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"MMP3 was linked to Krabbe disease pathology when its genetic ablation or chemical inhibition prevented psychosine-induced microglial globoid cell formation, a hallmark of the disease, with elevated MMP3 confirmed in twitcher mice.\",\n      \"evidence\": \"Primary glia from Mmp3-KO mice treated with psychosine, chemical MMP3 inhibitor, twitcher mouse model with bone marrow transplantation\",\n      \"pmids\": [\"23404611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct MMP3 substrate(s) mediating globoid cell morphological change unknown\", \"Whether MMP3 inhibition is therapeutic in twitcher mice not tested longitudinally\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"MMP3 was shown to amplify oncogenic signaling in pancreatic cancer by inducing Rac1b expression and cooperating with activated KRAS to drive acinar-to-ductal metaplasia and immune infiltration in vivo.\",\n      \"evidence\": \"Recombinant MMP3 treatment of pancreatic cancer cells, transgenic MMP3 + KRAS mice, invasion assays, human tissue correlation\",\n      \"pmids\": [\"24850902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which extracellular MMP3 induces Rac1b splicing change unclear\", \"Whether MMP3 acts upstream or in parallel to KRAS signaling not fully resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"The IRF8-MMP3 transcriptional axis was identified: IRF8 directly represses MMP3, and its loss elevates MMP3 to promote tumor growth and metastasis, with MMP3 knockdown rescuing the IRF8-loss phenotype.\",\n      \"evidence\": \"IRF8 stable silencing with MMP3 siRNA epistasis in orthotopic mammary carcinoma model, luciferase reporter\",\n      \"pmids\": [\"26008967\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether IRF8 binds MMP3 promoter directly via ChIP not shown\", \"Whether this axis operates in non-mammary tumor contexts unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A circadian clock link was established when BMAL1 deficiency was shown to enhance MMP3 transcription through NF-κB p65 phosphorylation, contributing to mandibular dysplasia.\",\n      \"evidence\": \"Bmal1-KO mice, RNA-seq, p65 phosphorylation assays, human SMH patient tissue\",\n      \"pmids\": [\"29276151\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BMAL1 directly occupies the MMP3 promoter or acts indirectly through p65 not resolved\", \"Temporal dynamics of MMP3 under circadian regulation not characterized\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"MMP3 was shown to promote tumor growth through both cell-autonomous signaling (via AKT/ERK phosphorylation and VEGFR1/FGFR3 maintenance) and intercellular extracellular vesicle transfer, where MMP3-containing EVs rescue MMP3-KO tumoroid growth and restore proliferation markers.\",\n      \"evidence\": \"MMP3 shRNA in prostate cancer cells with in vivo tumors and endothelial tube assays; CRISPR MMP3-KO tumoroids with EV transfer rescue\",\n      \"pmids\": [\"32896761\", \"32429403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether EV-delivered MMP3 acts catalytically at recipient cells not determined\", \"How MMP3 maintains VEGFR1/FGFR3 levels mechanistically unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"MMP3's role in blood-brain barrier integrity was mechanistically dissected: MMP3 activates ERK signaling to reduce tight junction and VE-cadherin proteins, and Mmp3-KO mice show reduced BBB permeability.\",\n      \"evidence\": \"Mmp3-KO mice with in vivo dye extravasation, TEER assays in WT and KO BMVECs, ERK inhibitor rescue\",\n      \"pmids\": [\"33859779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether MMP3 acts on TJ proteins directly via cleavage or indirectly through ERK not resolved\", \"Contribution of MMP3 relative to other BBB-disrupting MMPs (MMP2, MMP9) not compared\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Post-transcriptional regulation of MMP3 was uncovered when IGF2BP3 was shown to bind and stabilize MMP3 mRNA through m6A recognition, with MMP3 acting downstream to promote cardiomyocyte proliferation and cardiac regeneration.\",\n      \"evidence\": \"IGF2BP3 gain/loss-of-function, m6A-RNA interaction assays, mouse myocardial infarction model\",\n      \"pmids\": [\"37188676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific m6A site(s) on MMP3 mRNA not mapped\", \"How extracellular MMP3 promotes cardiomyocyte proliferation mechanistically unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"An epigenetic pathway to MMP3 upregulation was defined: loss of KMT2C/KMT2D histone methyltransferases leads to KDM6A-dependent H3K27me3 reduction at the MMP3 locus, derepressing MMP3 to drive TNBC brain metastasis.\",\n      \"evidence\": \"Kmt2c/Kmt2d KO in murine TNBC, H3K27me3 ChIP-seq, KDM6A knockdown and pharmacological inhibition, Mmp3 KD, in vivo metastasis assays, human patient tissue\",\n      \"pmids\": [\"38926506\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMP3 is the sole critical effector downstream of KDM6A in brain metastasis not excluded\", \"Direct chromatin occupancy of KDM6A at the MMP3 locus not shown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for MMP3 substrate selectivity in vivo, the identity of substrates mediating EMT and globoid cell formation, whether MMP3's diverse tissue-specific roles reflect different substrate repertoires or signaling functions independent of catalysis, and whether MMP3 inhibition is therapeutically viable given its context-dependent pro- and anti-tumorigenic activities.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No comprehensive in vivo degradome for MMP3 established\", \"Catalytic vs non-catalytic functions not systematically dissected\", \"Therapeutic window for MMP3 inhibition in cancer or neurodegeneration undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 20]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 20, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 3, 16, 20]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [1, 29, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 29, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 8, 17]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TIMP1\",\n      \"IGF2BP3\",\n      \"KDM6A\",\n      \"NFAT1\",\n      \"NFATc3\",\n      \"STAT3\",\n      \"IRF8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"MMP3 (stromelysin-1) is a secreted zinc-dependent endopeptidase synthesized as a proenzyme and activated stepwise by serine proteinases and autocatalytic intermolecular cleavage, with its catalytic zinc coordinated by conserved histidines and inhibited by TIMP-1 through bidentate Cys1–zinc chelation [PMID:3477804, PMID:2383557, PMID:9288970]. MMP3 degrades a broad spectrum of ECM substrates—including proteoglycan, fibronectin, laminin, type IV collagen, decorin, IGFBP-3, osteopontin, and myelin basic protein—and processes chemokines (MCP-1/2/3/4) into receptor antagonists that dampen inflammation, as well as cleaving FasL to promote osteoclast apoptosis downstream of estrogen/ERα signaling [PMID:3477804, PMID:9148753, PMID:12149192, PMID:22927007]. Transcription of MMP3 is induced by IL-1β, TNF-α, and adiponectin through convergent ERK/p38/JNK MAPK, NF-κB, and AP-1 pathways, with additional regulation by NFAT, STAT3, IRF8, and BMAL1, and a functional 5A/6A promoter polymorphism that modulates expression levels; post-transcriptionally, IGF2BP3 stabilizes MMP3 mRNA via m6A recognition [PMID:12009331, PMID:8662692, PMID:23625833, PMID:37188676]. MMP3 drives epithelial-to-mesenchymal transition, mammary tumor initiation, Rac1b-dependent pancreatic cancer progression, blood–brain barrier permeability via ERK-dependent tight junction degradation, and brain metastasis upon epigenetic derepression by KDM6A following KMT2C/D loss [PMID:10428026, PMID:24850902, PMID:33859779, PMID:38926506].\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Cloning of MMP3 cDNA established it as a secreted proenzyme with a zinc-binding catalytic domain homologous to thermolysin, placing it within the matrix metalloproteinase family.\",\n      \"evidence\": \"cDNA cloning and sequence analysis from human fibroblasts\",\n      \"pmids\": [\"3030290\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No enzymatic activity demonstrated\", \"No substrates identified\", \"Activation mechanism unknown\"]\n    },\n    {\n      \"year\": 1987,\n      \"claim\": \"Biochemical characterization of purified MMP3 defined its ECM substrate repertoire (proteoglycan, fibronectin, laminin, type IV collagen) and showed trypsin-mediated N-terminal propeptide removal generates the active 45-kDa enzyme.\",\n      \"evidence\": \"Protein purification, substrate cleavage assays, N-terminal sequencing, SDS-PAGE\",\n      \"pmids\": [\"3477804\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological activating proteinases unidentified\", \"Structural basis of catalysis unknown\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Detailed kinetic dissection revealed that proMMP-3 activation is a stepwise process: serine proteinases cleave the propeptide at distinct sites to generate intermediates, followed by bimolecular autolytic processing to the fully active species—establishing the activation cascade as a regulated multi-step event.\",\n      \"evidence\": \"Kinetic analysis and N-terminal sequencing of activation intermediates in vitro\",\n      \"pmids\": [\"2383557\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of individual serine proteinase activators not tested\", \"Cysteine-switch mechanism structurally unresolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Crystal structures of the proenzyme and catalytic domain of MMP3 resolved the cysteine-switch mechanism: the prodomain occupies the active site in reverse orientation relative to substrates, explaining latency.\",\n      \"evidence\": \"X-ray crystallography of proenzyme and catalytic domain\",\n      \"pmids\": [\"8535233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Inhibitor-bound structure not yet available\", \"S1' pocket substrate selectivity rules not defined structurally\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of a functional 5A/6A promoter polymorphism showed that differential nuclear protein binding regulates MMP3 transcriptional output, linking genetic variation to disease-relevant expression differences.\",\n      \"evidence\": \"CAT reporter assay, EMSA, DNase I footprinting in human cells\",\n      \"pmids\": [\"8662692\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the repressor protein(s) binding the 6A allele unknown\", \"Mechanism of allele-specific regulation incomplete\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"The MMP3–TIMP-1 co-crystal structure defined the inhibition mechanism: TIMP-1 Cys1 bidentately coordinates the catalytic zinc, and Thr2 inserts into the S1' pocket, explaining both broad MMP inhibition and specificity determinants.\",\n      \"evidence\": \"X-ray crystallography of MMP-3/TIMP-1 complex\",\n      \"pmids\": [\"9288970\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TIMP-2/3/4 inhibition mechanisms not compared structurally\", \"Dynamics of TIMP displacement during activation not studied\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Discovery that MMP3 cleaves decorin to release sequestered TGF-β1 expanded MMP3 function from simple ECM degradation to growth factor mobilization.\",\n      \"evidence\": \"In vitro cleavage assays with purified enzyme, N-terminal sequencing, TGF-β1 release assay\",\n      \"pmids\": [\"9148753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo physiological relevance of decorin-TGF-β1 release by MMP3 not demonstrated\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Transgenic MMP3 expression in mammary epithelium was sufficient to drive epithelial-to-mesenchymal transition and invasive tumor formation, rescued by TIMP1 co-expression, establishing MMP3 as a tumor initiator rather than merely a progression factor.\",\n      \"evidence\": \"Tet-regulated transgenic mouse, TIMP1 rescue, histopathology\",\n      \"pmids\": [\"10428026\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate(s) mediating EMT not identified\", \"Relevance to human breast cancer initiation not directly shown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"MMP3 cleavage of MCP chemokines between residues 4 and 5 generates truncated forms that act as receptor antagonists, revealing a novel anti-inflammatory role for MMP3 in modulating chemokine signaling.\",\n      \"evidence\": \"Purified enzyme cleavage, N-terminal sequencing, receptor binding, chemotaxis, and in vivo inflammation model\",\n      \"pmids\": [\"10947989\", \"12149192\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative in vivo contribution of MMP3 versus other MCPs-processing MMPs not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping of IL-1β-induced MMP3 transcription demonstrated convergent requirement for ERK, p38, JNK MAPK cascades plus AP-1 and NF-κB, establishing MMP3 as a hub target of multiple inflammatory signaling arms.\",\n      \"evidence\": \"Pharmacological MAPK inhibitors with RT-PCR readouts in human and bovine chondrocytes\",\n      \"pmids\": [\"12009331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each pathway under physiological stimulus concentrations unclear\", \"Promoter elements for each TF not mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Multiple studies revealed cell-type-specific transcriptional regulators of MMP3: NFATc3 drives calcium-dependent MMP3 induction in astrocytes, STAT3 activates MMP3 in brain endothelial cells, and estrogen/ERα induces MMP3 in osteoblasts where it cleaves FasL to control osteoclast apoptosis.\",\n      \"evidence\": \"Constitutively active NFATc3 OE/CsA inhibition/reporter in astrocytes; ChIP/reporter for STAT3 in endothelial cells; EGFP-FasL cleavage assay/MMP3 siRNA/ERαKO osteoblasts\",\n      \"pmids\": [\"23625833\", \"23967200\", \"22927007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether NFATc3 vs STAT3 vs ERα pathways converge on shared promoter elements is unknown\", \"FasL cleavage site not determined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"MMP3 was shown to stimulate Rac1b expression in pancreatic cancer cells and cooperate with oncogenic KRAS to drive acinar-to-ductal metaplasia and immune infiltration, defining a non-ECM signaling role in pancreatic tumorigenesis.\",\n      \"evidence\": \"Transgenic mice (MMP3 + KRAS), recombinant MMP3 treatment of cancer cells, invasion assays, human tissue analysis\",\n      \"pmids\": [\"24850902\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which MMP3 induces Rac1b splicing not identified\", \"Direct versus indirect Rac1b regulation unclear\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"ERK1 (not ERK2) was identified as the specific isoform phosphorylating ATF-2 to drive IL-1β-induced MMP3 expression in dermal fibroblasts, refining the MAPK-to-MMP3 signaling axis.\",\n      \"evidence\": \"Isoform-specific ERK1/ERK2 siRNA, ATF-2 inhibitor, Western blot of phospho-ATF-2\",\n      \"pmids\": [\"31536594\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether ERK1 specificity applies beyond dermal fibroblasts is untested\", \"Single lab, not independently replicated\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"MMP3 disrupts blood–brain barrier integrity through ERK-dependent degradation of tight junction and VE-cadherin proteins, demonstrated by MMP3 KO mice showing preserved barrier function and reduced dye extravasation.\",\n      \"evidence\": \"MMP3 KO mice, TEER/Transwell assays, in vivo dye extravasation, ERK inhibitor rescue\",\n      \"pmids\": [\"33859779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TJ protein cleavage sites not mapped\", \"Contribution of MMP3 versus secondary signaling to TJ loss not dissected\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Post-transcriptional regulation of MMP3 mRNA by IGF2BP3 through m6A recognition was identified, demonstrating that MMP3 output is controlled at the mRNA stability level in addition to transcriptional regulation, with functional relevance to cardiomyocyte proliferation and cardiac regeneration.\",\n      \"evidence\": \"RIP assay for IGF2BP3–MMP3 mRNA interaction, m6A analysis, gain/loss-of-function in mouse MI model\",\n      \"pmids\": [\"37188676\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific m6A sites on MMP3 mRNA not mapped\", \"Whether this mechanism operates in non-cardiac contexts unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Epigenetic derepression of MMP3 via KDM6A-mediated H3K27me3 removal upon KMT2C/D loss was shown to be necessary and sufficient for brain metastasis in triple-negative breast cancer, establishing MMP3 as a critical effector downstream of chromatin dysregulation.\",\n      \"evidence\": \"KMT2C/D KO mice, ChIP-seq (H3K4me1/H3K27ac/H3K27me3/KDM6A), MMP3 shRNA, KDM6A inhibitor, in vivo brain metastasis, human TNBC samples\",\n      \"pmids\": [\"38926506\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MMP3 is the sole mediator of KMT2C/D-loss brain metastasis or one of several effectors is unresolved\", \"Substrate(s) mediating BBB crossing not identified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of direct MMP3 substrate(s) mediating EMT and brain metastasis, the structural basis for Rac1b induction, whether extracellular vesicle–mediated MMP3 transfer is physiologically significant, and comprehensive mapping of MMP3 cleavage sites in the degradome in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No in vivo degradomic/TAILS study of MMP3 substrates\", \"EV-mediated MMP3 delivery lacks independent validation\", \"Rac1b induction mechanism completely uncharacterized\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 3, 4, 8, 11, 12, 16, 17, 22]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 3, 4, 8, 11, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 9, 32]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [1, 8, 12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [1, 8, 12, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 26, 27, 28, 37]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11, 17]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 21, 31, 34]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TIMP1\",\n      \"NFATC3\",\n      \"IGF2BP3\",\n      \"KDM6A\",\n      \"STAT3\",\n      \"IRF8\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}